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ABSTRACT
We compared the frequency of rhinorrhea between 34 Parkin-
son’s disease (PD) subjects and 15 normal controls (NC) and
explored relationships between rhinorrhea and clinical func-
tions, and degree of nigrostriatal dopaminergic denervation
using [11C]dihydrotetrabenazine (DTBZ) brain positron emission
tomography imaging. Sixty-eight percent (23 of 34) of PD sub-
jects reported rhinorrhea of any cause compared with 27% (4 of
15) of NC (v2 5 7.07, P 5 0.008). Rhinorrhea frequency
remained higher in the PD group after excluding possible rhinitic
etiologies: 35% (12 of 34) of PD versus 7% (1 of 15) of NC (v2 5
4.38, P 5 0.04). There were no differences in demographics, ni-
grostriatal dopaminergic denervation, and clinical motor or non-
motor variables between PD subjects with and without
rhinorrhea, except that more PD subjects with rhinorrhea com-
plained of lightheadedness (52% vs. 9%, v2 5 5.85, P 5 0.02).
Rhinorrhea is a common nondopaminergic feature of PD, unre-
lated to olfactory or motor deficits. Further investigations are
needed to determine if rhinorrhea correlates with sympathetic
denervation or other autonomic symptoms in PD.VC 2010 Move-
ment Disorder Society
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Rhinorrhea, defined in previous studies involving
patients with Parkinson’s disease (PD) as the presence
of a runny nose unrelated to allergies, respiratory
infections, or sinus problems, has been reported to
occur more frequently among PD patients than
healthy controls.1,2 The two existing studies on rhinor-
rhea in PD have originated from only one center,1,2
and it remains unclear if rhinorrhea is common to all
PD patients or restricted to a specific geographic
region.
Friedman and coworkers have hypothesized that
rhinorrhea in PD may be due to sympathetic denerva-
tion of the nasal mucosa1,2 but they did not investi-
gate other autonomic signs or symptoms. The
association of rhinorrhea with olfaction, motor func-
tion, and nigrostriatal dopaminergic denervation on
positron emission tomography (PET) imaging has also
not been explored. One study reported an association
between rhinorrhea and hyposmia, but olfaction was
assessed by self-report only.1
In this study, we compare the frequency of rhinor-
rhea between PD subjects and normal controls (NC)
and investigate the relationship between rhinorrhea
and clinical (olfaction, motor, and autonomic) fea-
tures, and the degree of nigrostriatal dopaminergic de-
nervation in PD. We hypothesized that (1) rhinorrhea
would be more prevalent in PD than in NC, (2) rhin-
orrhea would be unrelated to olfaction, motor func-
tion, or nigrostriatal dopaminergic denervation in PD
patients, and (3) rhinorrhea would be related to other
autonomic problems in PD.
Patients and Methods
Subjects and Patient Consents
Thirty-four men between 50–85 years of age meet-
ing UK PD Society Brain Bank criteria for PD3 were
enrolled in this study. These subjects were originally
recruited for a study on falls in PD. For that study,
they had to be ambulatory, nondemented (defined as
Mini-Mental State Exam MMSE  25), willing to
undergo brain PET imaging, and could not be taking
cholinesterase inhibitors or pure anticholinergic drugs.
All were recruited prospectively from the Neurology
and Geriatric, Research, Education, Clinical Center
clinics at the Veterans Affairs (VA) Hospital. The di-
agnosis of PD was confirmed by nigrostriatal dopami-
nergic denervation on [11C]dihydrotetrabenazine
(DTBZ) vesicular monoamine transporter type 2
(VMAT2) brain PET imaging. The mean Unified PD
Rating Scale (UPDRS) motor score was 27.6 6 7.3
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(range 15–45) and mean disease duration was 6.2 6
3.1 years (range 0.5–12). All PD subjects were on do-
paminergic treatment but none on apomorphine.
Fifteen male NC were recruited from existing data-
bases/advertisements. They had no known neurologi-
cal or psychiatric illness, or family history of
significant neurological or psychiatric illness in first-
degree relatives. All had MMSE  25. None were tak-
ing centrally acting medications.
All participants were nonsmokers with no history of
trauma or concurrent respiratory infection that could
interfere with olfaction. None had clinically significant
abnormalities (i.e., large vessel strokes, excessive white
matter changes, or tumors) on brain MRI. Participants
gave informed written consent, and the protocol was
approved by the Institutional Review Boards of the
University of Michigan and the Ann Arbor VA (Clini-
calTrials.gov identifier: NCT00736671).
Clinical Testing Procedures
Participants were asked if they had a runny nose,
allergies, sinus problems, or frequent colds/respiratory
infections. Participants had rhinorrhea if they
answered yes to the question ‘‘Do you have a runny
nose?’’ A stricter definition, nonrhinitic rhinorrhea,
was considered if participants had a runny nose but
no allergies, sinus problems, or frequent colds/respira-
tory infections. This stricter definition was used in pre-
vious studies.1,2
Participants were asked (using a yes/no format) if
they experienced subjective lightheadedness or passed
out during the past year, had a problem with ‘‘dusky
hands,’’ or experienced bladder problems, erectile dys-
function or constipation. They were also asked about
the presence of diabetes or prostate problems to rule
out possible confounding factors. Orthostatic blood
pressures were measured. Medications reported to
cause rhinorrhea,4 including antihypertensives, a-
antagonists, aspirin, and other nonsteroidal anti-
inflammatory agents, were recorded. Olfaction was
assessed using the 40-item University of Pennsylvania
Smell Identification Test (UPSIT; Sensonics, Haddon
Heights, NJ).5 Motor severity was assessed using the
UPDRS motor subsection. PD subjects were tested and
imaged in the morning after withholding dopaminergic
medications overnight.
Imaging Techniques and Data Analysis
DTBZ PET image acquisition and analysis has been
described previously.6 The binding potential relative
to the nondisplaceable uptake (BPND) was estimated
as before,6 except that for this analysis, the whole
neocortex was used as a reference region instead of
the occipital cortex for more robust assessment.
Group comparisons were performed using standard t
tests or v2 analyses as appropriate. Data were ana-
lyzed using SAS, version 9.1 (SAS Institute, Cary, NC,
USA).
Results
Rhinorrhea Frequency in PD and NC
Rhinorrhea of any cause occurred more frequently
in PD compared with NC (68% of PD vs. 27% of
NC; v2 ¼ 7.07, P ¼ 0.008, see Table 1). Nonrhinitic
rhinorrhea was five times more prevalent in PD than
NC (35% vs. 7%; v2 ¼ 4.38, P ¼ 0.04). Mean UPSIT
scores and VMAT2 BPND activity throughout the
striatum were significantly lower in the PD group (Ta-
ble 1). There was no difference in age or rhinorrhea
medications between the patients and controls, but
NC had a slightly higher MMSE score (t ¼ 2.10, P ¼
0.04).
PD Subjects with and Without Rhinorrhea
There were no differences in most clinical variables,
including baseline demographics, motor function, au-
tonomic symptoms, olfactory performance, and stria-
tal VMAT2 binding using DTBZ PET between PD
subjects with and without rhinorrhea (Table 2). There
TABLE 1. Baseline characteristics between Parkinson’s disease (PD) and normal control (NC) subjects
PD (n ¼ 34) NC (n ¼ 15) Statistic P value
Age (y) 68.3 6 8.2 66.6 6 11.7 t ¼ 0.59 0.56
No. (%) with rhinorrhea (any cause) 23 (68) 4 (27) v2 ¼ 7.07 0.008
No. (%) with nonrhinitic rhinorrhea 12 (35) 1 (7) v2 ¼ 4.38 0.04
No. (%) on medications with potential to cause rhinorrhea 20 (59) 6 (40) v2 ¼ 1.48 0.22
UPSIT scores 16.5 6 8.3 32.2 6 6.9 t ¼ 6.35 <0.0001
MMSE 29.0 6 1.4 29.6 6 0.6 t ¼ 2.10 0.04
VMAT2 BPND activity
Caudate 1.02 6 0.42 1.59 6 0.24 t ¼ 5.96 <0.0001
Anterior putamen 0.90 6 0.40 2.20 6 0.33 t ¼ 11.03 <0.0001
Posterior putamen 0.63 6 0.34 2.44 6 0.35 t ¼ 16.68 <0.0001
Total striatum 0.92 6 0.31 1.95 6 0.26 t ¼ 11.09 <0.0001
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were also no differences in the frequency of diabetes
or prostate problems between the 2 groups.
The rhinorrhea group had slightly lower MMSE
scores (t ¼ 2.11, P ¼ 0.04) and complained more
about lightheadedness (52% vs. 9%; v2 ¼ 5.85, P ¼
0.02) compared with the nonrhinorrhea PD group.
There was also a trend toward a prior history of pass-
ing out (P ¼ 0.09) and lower sitting systolic blood
pressures (P ¼ 0.09) in PD subjects with rhinorrhea.
When using a stricter definition of rhinorrhea, there
were no significant differences in any baseline demo-
graphic, motor, olfactory, autonomic, or PET varia-
bles, including MMSE, subjective lightheadedness,
passing out, and sitting systolic blood pressures.
Discussion
Our results are consistent with the findings of
Friedman and coworkers1,2 that a runny nose not
due to allergies, sinus problems, or colds occurs
more frequently in PD than non-PD subjects. We
further extend these findings and demonstrate that
both rhinorrhea due to any cause and nonrhinitic
rhinorrhea are unrelated to severity of nigrostriatal
dopaminergic activity, or olfactory and motor dys-
function in PD.
The prevalence of nonrhinitic rhinorrhea in our PD
subjects (35%) was lower than previously reported
(50%).1,2 This could be due to our smaller sample
size or the fact that our PD population was comprised
of only men. Nonrhinitic rhinorrhea tends to occur
more commonly in women with PD, with one study
reporting a frequency of 68% in women and 33% in
men,1 a figure more consistent with our findings.
Previous studies on rhinorrhea in PD have
reported an association with olfactory impairment,
but the presence of olfactory impairment was ascer-
tained by self-report only.1 We objectively tested
odor identification using the UPSIT in this study
and found no significant differences between PD
patients with and without rhinorrhea, regardless of
the rhinorrhea definition used. This is consistent
with the observation that PD patients are hyposmic
in general7 and suggests that rhinorrhea is unrelated
to olfaction.
While nigrostriatal pathology correlates with specific
motor symptoms in PD, it is now recognized that non-
motor comorbidities extend beyond the loss of dopa-
minergic nigral neurons.8 We found no gross
differences in striatal VMAT2 binding using DTBZ
PET between PD subjects with and without rhinorrhea
but our sample size was small. These findings suggest
that rhinorrhea can be added to the growing list of
nondopaminergic features in PD and are also consist-
ent with the possibility that rhinorrhea may be due to
sympathetic denervation.1,2 Sympathetic denervation
in the heart has been reported in PD,9 but it is unclear
if sympathetic dysfunction also occurs in the nasal mu-
cosa. If it does, it may leave unopposed parasympa-
thetic stimulation, which increases nasal secretions.2
We did not perform cardiac noradrenergic PET imag-
ing in this study but investigated other autonomic
symptoms. The percentage of PD subjects with consti-
pation, bladder problems, erectile dysfunction, or
TABLE 2. Comparison of clinical variables and VMAT2 BPND activity in PD subjects with and without rhinorrhea
Rhinorrhea þ (n ¼ 23) Rhinorrhea  (n ¼ 11) t statistic P value
Age (y) 68.8 6 7.9 67.3 6 9.2 0.51 0.61
Disease duration (y) 6.2 6 3.1 6.3 6 3.2 0.15 0.89
No. (%) on medications with potential to cause rhinorrhea 15 (65) 5 (45) v2 ¼ 1.20 0.27
MMSE 28.7 6 1.5 29.5 6 0.7 2.11 0.04
UPSIT score 17.5 6 9.0 14.4 6 6.3 0.98 0.33
UPDRS motor 28.0 6 8.0 26.6 6 6.0 0.53 0.60
No. (%) with lightheadedness 12 (52) 1 (9) v2 ¼ 5.85 0.02
No. (%) who have passed out 5 (22) 0 (0) v2 ¼ 2.80 0.09
SBP sitting (mm Hg) 120.0 6 15.3 128.9 6 11.5 1.70 0.09
DBP sitting (mm Hg) 74.7 6 6.1 77.5 6 9.6 1.04 0.31
Change in SBP with standing (mm Hg) 2.9 6 7.1 4.3 6 6.1 0.56 0.58
Change in DBP with standing (mm Hg) 1.9 6 3.9 0.5 6 6.1 0.80 0.43
No. (%) with bladder problems 15 (65) 7 (64) v2 ¼ 0.008 0.93
No. (%) with constipation 12 (52) 3 (27) v2 ¼ 1.88 0.17
No. (%) with dusky hands 2 (9) 0 (0) v2 ¼ 1.0 0.31
No. (%) with impotence 15 (65) 5 (45) X2 ¼ 1.20 0.27
VMAT2 BPND activity
Caudate 1.02 6 0.43 1.02 6 0.41 0.02 0.99
Anterior putamen 0.93 6 0.41 0.82 6 0.38 0.71 0.48
Posterior putamen 0.66 6 0.37 0.59 6 0.28 0.51 0.61
Total striatum 0.92 6 0.31 0.90 6 0.34 0.19 0.85
SBP, systolic blood pressure; DBP, diastolic blood pressure.
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dusky hands did not differ between the rhinorrhea and
nonrhinorrhea groups, regardless of the rhinorrhea
definition used. However, patients with rhinorrhea of
any cause had more subjective lightheadedness and a
trend toward more frequent passing out and lower
systolic blood pressures when sitting. These findings
were no longer significant after excluding those with a
rhinitic cause of rhinorrhea, but we may have had too
small a sample size to detect such a difference. Further
investigations are clearly needed to see if rhinorrhea
correlates with cardiac and/or cerebral sympathetic de-
nervation or other autonomic symptoms in PD.
A limitation of the study is that we did not study
women as our patients were recruited from a VA pop-
ulation. Another limitation is that the presence of
rhinorrhea was established by questionnaire only.
Anatomic causes of rhinorrhea such as nasal polyps,
which are common in men and the elderly,10 cannot
be completely excluded. It is possible that rhinorrhea
was caused by medications in some subjects, but
group comparisons showed no differences in the pro-
portion of participants taking medications with the
potential to induce rhinorrhea.
In summary, rhinorrhea is a common, nondopami-
nergic feature in PD that is unrelated to the severity of
olfactory or motor deficits. The relationship between
rhinorrhea, sympathetic denervation, and autonomic
dysfunction needs to be further explored using vali-
dated questionnaires.
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ABSTRACT
Present pathophysiological concepts of neuropathic tremor
assume mistimed and defective afferent input resulting in
deregulation of cerebello-thalamo-cortical motor networks.
Here, we provide direct evidence of central tremor processing
in a 76-year-old female who underwent bilateral deep brain
stimulation of the ventral intermedial nucleus of the thalamus
(Vim-DBS) because of neuropathic tremor associated with IgM
paraproteinemia. Electrophysiological recordings of EEG and
EMG were performed in three perioperative sessions: (1) preop-
eratively, (2) intraoperatively, and (3) 4 days after surgery in both
rest and postural tremor conditions. Tremor-related synchroni-
zation (coherence) between motor cortex (M1) and muscles (M.
extensor digitorum, M. flexor digitorum) was assessed, and
additional intraoperative local field potential (LFP) recordings
from Vim allowed comprehensive coherence mapping in tha-
lamo-cortico-muscular networks. Directionality of information
flow was determined by directed transfer function (DTF) and
phase analyses. Stimulation effects on tremor and
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corticomuscular coherence were assessed and the patient was
followed for 12 months on clinical outcome measures (Tremor
Rating Scale, CADET-Score). Vim-DBS reduced tremor (59%)
and improved motor functionality in daily activities (31%, CA-
DET-A) after 12 months. Intraoperative recordings demon-
strated significant coherence in the tremor frequency (4 Hz)
between M1 and contralateral muscle, Vim and ipsilateral M1,
Vim and contralateral muscle, but not between Vim and contra-
lateral M1. Information flow was directed from M1 to Vim and
bidirectional between M1 and muscle and between Vim and
muscle, respectively. Corticomuscular coherence at tremor fre-
quency was completely suppressed by Vim-DBS. Our case
study demonstrates central oscillators underlying neuropathic
tremor and implies a strong pathophysiological rationale for
Vim-DBS.VC 2010Movement Disorder Society
Key Words: neuropathy; tremor; deep brain stimulation;
coherence; local field potentials
Tremor occurs in up to 40–90% of the patients with
IgM paraproteinemic neuropathy1 and remains refrac-
tory on medical treatment in the majority of patients.1,3
Present pathophysiological concepts of neuropathic
tremor postulate that distorted mistimed peripheral
inputs reach a central processor, which is misled into
producing tremor.3,4 Therapeutic effectivity of deep
brain stimulation of the ventral intermedial nucleus of
the thalamus (Vim-DBS) in a few single cases pointed to
maladaptive central motor processing,2 although no
direct evidence was presented. To explore the present
pathophysiological concept, we hypothesized on the
presence of neuronal and neuromuscular synchroniza-
tion (coherence) related to the tremor frequency as a
substrate of central tremor processing based on intra-
and perioperative recordings of oscillatory activity in a
patient who underwent Vim-DBS.
Patients and Methods
Patient and Surgery
In 2005, the patient (76-year-old, female) developed
bilateral kinetic and postural tremor (absent at rest)
with pronunciation of the distal upper extremities
paired with sensory gait disorder, loss of deep tendon
reflexes, and pallanesthesia of the malleoli mediales.
In 2007, IgM-paraproteinemia related to lymphoblas-
mocytic lymphoma was diagnosed. Neurography
revealed axonal demyelinating sensorimotor neuropa-
thy (Table 1) and in 2008, IgM neuropathy was dem-
onstrated by sural nerve biopsy. Tremor was not
responsive to alcohol as documented under clinical
survey and no family history for tremor was reported.
Genetic analysis excluded fragile X associated tremor
ataxia syndrome [fragile X tremor ataxia syndrome
(FXTAS)]. Since pharmacological treatment with pro-
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not improve tremor, bilateral Vim-DBS was performed
in 2008 awake during surgery procedure. Three intra-
operative trajectories on the right Vim (T1 ¼ central
trajectory, T2 ¼ posterior trajectory, T3 ¼ lateral tra-
jectory) were subjected to local field potential (LFP)
recordings. Trajectory T2 yielded best clinical effectiv-
ity upon intraoperative test stimulation and was there-
fore implanted. Postoperative imaging confirmed
proper electrode placement (refer supporting
information).
Clinical Evaluation and Paradigm
The study was approved by the local ethics commit-
tee and the patient gave informed written consent.
The ‘‘Tremor Rating Scale’’ and ‘‘Columbia University
Assessment of Disability in Essential Tremor (CADET)
score, appendix A’’5 were assessed before, 3 and 12
months after surgery, respectively. Recordings of EEG
and EMG were performed (1) 1 month before surgery,
(2) intraoperatively (including simultaneous Vim-LFP
recordings), and (3) 4 days after surgery. In each of
the sessions, recordings at rest and during postural
tremor (both arms elevated separately, anteversion
90, elbow stretched 160, hand in supination) were
performed. In the postoperative session, Vim-DBS was
either stimulation turned off (StimOff) or stimulation
turned on (StimOn) unilaterally both (1) ipsi- and (2)
contralateral to the trembling arm.
Data Analysis
Data analysis was performed using Matlab 7.0 (The
MathWorks, Natick, MA) and included (1) frequency
domain analysis of muscular activity, (2) coherence
analysis, and (3) directionality analysis based on
directed transfer function (DTF) and the maximizing
phase synchronization index. Both Vim and EEG sig-
nals were bipolarized before computing the spectral
measures. Significance of the coherence spectra was
tested using a 99% confidence limit. The pair of chan-
nels displaying a significant coherence maximum at
tremor frequency was selected for analysis on direc-




Tremor caused severe motor impairment in daily
activities at the preoperative baseline (Tremor Rating
Scale: 20 points, CADET-A: 60 points). Bilateral Vim-
DBS led to a marked improvement in the Tremor Rat-
ing Scale (67% at 3 months, 59% at 12 months) and
in the CADET-A (40% at 3 months, 31% at 12
months), however the stimulation amplitude had to be
consecutively raised within the first year to achieve
stable therapeutic effects. Neurographic parameters
remained stable in the follow-up period (Table 1).
Tremor-Related Coherence
Preoperatively, significant corticomuscular coherence
at tremor frequency (4 Hz) was present between left
muscles and contralateral motor cortex (M1) during
postural tremor (absent at rest) with maxima on C4CP4
and C2CP2. This was reproduced in intraoperative
recordings and additional significant coherence between
right Vim and right M1 (maximum T1T2-C4CP4) at 4
Hz and in the first harmonic frequency (8–9 Hz) was
found. This coherence peak was smaller but still signifi-
cant on T1T3-C4CP4 and absent on T2T3-C4CP4. No
significant coherence was present between right Vim
and left M1. Thalamo-muscular coherence at 4 Hz dis-
played a similar pattern with coherence maxima on
T1T2-muscles, smaller significant coherence on T1T3-
muscles, but no significant coherence on T2T3-muscles
(Fig. 1). No significant coherence between Vim, M1,
and muscles was found at rest.
Directionality and Conduction Time of
Tremor-Related Oscillatory Activity
Phase analysis and DTF were performed on T1T2-
muscle, T1T2-C4CP4, and C4CP4-muscle. There was
a delay of 19 ms from muscle to Vim and of 9 ms
from Vim to muscle. DTF analysis showed unidirec-
tional feedforward flow from Vim to muscle. A unidir-
ectional flow from C4CP4 to Vim with a delay of 7
ms was consistent with DTF analysis showing strong
flow from M1 to Vim and only sparse inverse flow.
Bidirectional flow delayed by 10 ms from C4CP4 to
muscle and 32 ms from muscle to C4CP4 was found.
DTF showed unidirectional feedforward flow from
M1 to muscle (supporting information Fig. 1).
Effects of Vim-DBS on Postural Tremor
Muscular power and intermuscular coherence were
marked at 4 Hz (StimOff) and reduced upon Vim-DBS,
but increased between 10 and 40 Hz. No frequency
shift of the tremor-related peak was observed. Cortico-
muscular coherence at 4 Hz (StimOff) was suppressed
by stimulation (supporting information Fig. 2). If the
Vim ipsilateral to the trembling muscle was stimulated
(contralateral StimOff), the corticomuscular coherence
remained unchanged, as expected (not shown).
Discussion
We provide evidence for central oscillators underly-
ing neuropathic tremor. Tremor was associated with
synchronous oscillatory activity at 4 Hz in a network
including Vim and M1 contralateral to the trembling
muscle (absent at rest). This was suppressed by Vim-
DBS in parallel with a marked tremor reduction.
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Several aspects of our findings support its patho-
physiological significance and argue against a major
influence of mechanical artefacts inevitably arising
from tremor in electrophysiological recordings: (1)
corticomuscular coherence at tremor frequency was
paralleled by local maxima of tremor-related coher-
ence from Vim (T1T2) to both ipsilateral M1 and con-
tralateral muscles. One may argue, whether thalamo-
cortical and thalamo-muscular coherence was brought
in by volume conduction from corticospinal fiber
tracts descending laterally from Vim. However, T3
(the most lateral trajectory) displayed weak coherence
in bipolar T1T3 and no significant coherence in T2T3
indicating a local maximum on T1T2. In accordance
to the topographical coherence distribution test stimu-
lation on T2 improved tremor. Test stimulation on
T3, however, failed to improve tremor but showed the
lowest threshold for capsular side effects from test
stimulation, as expected (supporting information Ta-
ble 1). (2) Corticomuscular coherence at tremor fre-
quency presented lateralized on the M1 contralateral
to the trembling arm in each of the perioperative con-
ditions and was suppressed by Vim-DBS together with
strong reduction of tremor on both clinical and elec-
trophysiological measures. Moreover, muscular power
and intermuscular coherence increased within a broad
range of the beta band, as known from physiological
isometric contraction.6,7 (3) Directionality analysis of
tremor-related coherence revealed non-zero phase
delays between Vim, M1, and muscle. Muscular activ-
ity was driven forward from both M1 and Vim and
reafference lagged the feedforward drive. Similar con-
duction delays from both Vim and M1 to muscle
might raise the question whether both are coupled to
a third oscillator, e.g. cerebellum.3,4 Alternating out-
put from both oscillators to muscle would also explain
the condition.8 As expected, reafferent flow from mus-
cle to M1 or Vim was not represented by the DTF
analysis due to the higher signal strength in muscle.8,9
The phase analysis (insensitive to the amplitude of the
signal) can correctly capture the driver-response rela-
tionship in neuromuscular projections whereas the
DTF (sensitive to the amplitude of the signal) reliably
establishes driver-response relations between EEG and
VIM due to comparable signal strengths.
Clinical Aspects of Vim-DBS in
Neuropathic Tremor
Absence of other well characterized tremor condi-
tions is mandatory in order to diagnose ‘‘neuropathic
tremor.’’ Tremor occurs with high prevalence in
patients with paraproteinemic neuropathy and further
clinical signs of our patient including ataxia of gait,
temporally coincident onset of neuropathy, missing
therapeutic response to alcohol, and negative family
FIG. 1. Intraoperative coherence mapping between Vim, cortex, and muscle. Coherence spectra from intraoperative recordings during postural
tremor of the left arm. A Left/right cortex–muscles. B Right Vim–right cortex. C Right Vim–left muscles. D coherence spectra at rest. The x-axis: fre-
quency [Hz] and y-axis: coherence. Horizontal line: 99% confidence limit. Note that no significant coherence was present during the postural tremor
condition between right Vim and left contralateral cortex (data not shown).
326 Movement Disorders, Vol. 26, No. 2, 2011
W E I S S E T A L .
history matched the clinical characteristics.3 Vim-DBS
in our patient improved both postural and kinetic
components of the tremor. Best tremor suppression
was achieved on the most ventral (caudal) contacts on
AC-PC level. This is in line with previous findings in
patients with essential tremor and therapeutic effects
might rather arise from crossing cerebello-thalamic
projection fibers in the subthalamic white matter than
from the Vim itself.11 The stimulation intensity had to
be increased between the 3-month and 12-month fol-
low-up in our patient. Neurographic parameters
remained stable and argue against a relevant progres-
sion of neuropathy although this cannot completely
rule out a worsening of the tremor severity in the re-
spective time range.3 The conduction delay of tremor
feedback from muscle to M1 (32 ms) in our patient
exceeded the phase delays in patients with essential
tremor upon the same methodological approach.8
Interestingly, similar delays in sensory evoked poten-
tial N20 conduction times (30–48 ms) were described
in patients with neuropathic tremor.3 Whether delayed
reafference of the tremor phase constitutes a specific
electrophysiological marker of neuropathic tremor,
however, remains to be established. Our findings sup-
port the concept of maladaptive central motor proc-
essing in neuropathic tremor and therefore provide a
strong pathophysiological rationale for Vim-DBS.
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ABSTRACT
Molecular imaging studies of Parkinson’s disease (PD) pro-
gression mostly focus on the first 5 years after disease onset,
demonstrating rapid initial nigrostriatal neuronal loss. The fate
of residual functional dopaminergic nerve terminals in patients
with long-standing PD has not yet been specifically explored.
Therefore, we performed [123I]-FP-CIT single photon emission
computed tomography (SPECT) in 15 patients with very long-
standing PD (mean disease duration 20.6 6 6.3 years). Meas-
urable uptake of [123I]-FP-CIT was still detected in the striata
of all patients. As seen in early stages, reduction of tracer
uptake in the putamen was more prominent than in the cau-
date nucleus. Asymmetry in tracer uptake between the two
putamen and caudate nuclei was preserved. These findings
indicate that degeneration of dopaminergic neurons in PD is
not total even after many years of illness. Data should be con-
sidered in exploring underlying causes of progressive loss of
nigrostriatal dopaminergic neurons and development of future
novel dopaminergic therapeutic strategies in PD. VC 2010
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There is a recent increasing interest in Parkinson’s
disease (PD) patients with very long-standing illness.
Hely et al.1,2 showed that after 20 years of illness,
there is a shift of symptom burden from nigrostriatal
to extranigral sites. This raises intriguing questions
regarding the fate of dopaminergic neurons in
advanced PD, i.e., are they totally lost, are there dif-
ferences in survival between nigro-putaminal and
nigro-caudal projections, and whether the asymmetry
of neuronal loss is still maintained.
Functional imaging is a powerful approach to study
the underlying neuropathology in PD. However, stud-
ies using positron emission tomography with 18F-dopa
and single photon emission computed tomography
(SPECT) with ligands for the presynaptic dopamine
transporters (DaT), mainly focused on patients during
the first 5 years after disease onset,3–6 and imaging
data of patients with extreme ‘‘end stage’’ of PD is
lacking.
We have therefore evaluated the pattern of striatal
uptake of [123I]-FP-CIT in PD patients with disease
durations of more than 15 years.
Patients and Methods
Patients
A total of 15 patients with idiopathic PD were en-
rolled in the study. The study was approved by the
local ethics committee and a written informed consent
was obtained from all subjects. Diagnosis was based
on the UK PD Society Brain Bank criteria.7 Disease se-
verity was assessed according to the Unified PD Rating
Scale (UPDRS), and the Hoehn and Yahr (H&Y)
scale, evaluated during the ‘‘on’’ stage. Asymmetry
index was calculated by subtracting the UPDRS score
of the less affected from the more affected side. Cogni-
tive status was assessed by the Mini Mental Status Ex-
amination. The results were compared to 11 healthy
controls.
SPECT Studies
All patients received potassium iodide orally to
block thyroid uptake of free radioactive iodide. A
dose of 185 MBq [123I]-FP-CIT was injected intrave-
nously and imaging was performed 3 hours later. The
SPECT study was performed using a dual-head c-cam-
era (Helix; Elscint) equipped with a low-energy, high-
resolution collimator. A 20% window was centered
on the 159-keV photopeak of 123I. One hundred
twenty frames (of 15 seconds) were acquired using a
circular rotation mode into a 128  128 image ma-
trix. Transaxial, coronal, and sagittal slices 1-pixel
thick were reconstructed using a third-order Metz fil-
ter set to 12-mm full width at half maximum. Attenu-
ation correction was performed with a constant linear
attenuation coefficient of 0.11 cm1. As patients were
not able to ambulate without medications, they were
allowed to take levodopa before the SPECT
procedure.
Analysis of SPECT Results
For analysis of striatal [123I]-FP-CIT binding, the
two transaxial slices representing the most intense
striatal binding were summed and subjected to quali-
tative analysis of tracer activity in the striatal regions.
For quantitative analysis of tracer uptake, regions-of-
interest (ROIs) were constructed manually with the
help of a brain atlas in areas corresponding to the
right and left putamen, caudate, and overall striatum.
For background evaluation, ROIs were also drawn
bilaterally in areas corresponding to the medial occipi-
tal lobe. For each ROI, mean counts were measured
and specific [123I]-FP-CIT uptake was then calculated,
according to the following formula: Specific [123I]-FP-
CIT uptake ¼ (mean activity in ROI  mean activity
in occipital cortex)/mean activity in occipital cortex).
SPECT analysis was performed by a Nuclear Medicine
expert, blinded to the patient’s disease duration.
Statistical Analysis
t Test was used to compare between mean FP-CIT
uptake of the putamen, caudate, and striatum of
patients and controls. Paired t test was used to com-
pare between mean FP-CIT uptake in both sides of the
putamen and mean uptake in the caudate, and to eval-
uate differences within each patient between the more
and less affected sides of the putamen, caudate, and
overall striatum. Correlation between FP-CIT values
and UPDRS and asymmetry index was assessed using
Pearson test. Data are presented as mean 6 SD.
Results
Clinical Characteristics
The clinical characteristics and FP-CIT uptake val-
ues of the patients and of controls are summarized in
Table 1. Mean age of the patients was 68 6 8.6 years
(compared with 61 6 12 years in the control group; P
< 0.001) and mean disease duration 20.6 6 6.3 years.
Fourteen of fifteen patients had motor fluctuations,
and 13 of 15 patients had dyskinesias. The patients
had a UPDRS score at ‘‘on’’ of 30.4 6 15.5 (mean 6
SD).
FP-CIT uptake was reduced by 87% in the puta-
men, by 72% in the caudate, and by 78% in the stria-
tum in patients compared with controls (Table 1).
Qualitative analysis of the SPECT data revealed resid-
ual [123I]-FP-CIT uptake in the striata of all patients
at this advanced disease stage. The most robust uptake
was observed in the caudate nucleus. Quantitative
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analysis showed that the putamen is more denervated
than the caudate nucleus. Mean uptake of both sides
of the putamen was significantly reduced compared
with mean uptake of both sides of the caudate (0.38
6 0.24 vs. 1.16 6 0.39; P < 0.001).
To evaluate the natural course of this asymmetry
between the right and left striata in the advanced
stages of the disease, we compared [123I]-FP-CIT
uptake in the more versus the less affected side. The
putamen and caudate contralateral to the side of
greater motor disability was associated with a larger
reduction in tracer uptake, in comparison with the ip-
silateral side. It was more prominent in the putamen
(0.34 6 0.26 in the more affected vs. 0.42 6 0.24 in
the less affected side; P < 0.0001) than in the caudate
(1.02 6 0.45 in the more affected vs. 1.15 6 0.38 in
the less affected side; P < 0.01). There was correlation
between FP-CIT uptake in the putamen, caudate, and
striatum and UPDRS score (P < 0.003, P < 0.002,
and P < 0.003, respectively). However, there was no
significant correlation between FP-CIT values and
asymmetry index.
Discussion
This study presents the in vivo status of dopaminer-
gic nerve terminals in the striatum of patients with
very long-standing disease, with a mean duration of
21 years.
Our main finding in this unique group of patients is
that there still are residual functional dopaminergic
nerve terminals in the striatum, even in such advanced
stage of disease. This implies that even after very long
disease course, the dopaminergic nigrostriatal projec-
tions are not totally lost. Our findings are in agree-
ment with previous imaging studies in patients with
disease duration of up to 26 years, which demon-
strated that ligand uptake was still detected in all
parts of the striatum. Asymmetry between the more
and less affected side remained, although less promi-
nent than in early stages of the disease.8–11 This study,
however, expands the characterization of striatal
[123I]-FP-CIT uptake profile to much longer disease
durations. These results seem to correlate with clinical
evidence from the Sydney cohort study showing that
after 15 to 20 years of illness, dopamine-dependent
motor manifestations reach a plateau and nonmotor
or motor nondopaminergic features supervene and
become much more important at this advanced disease
stage.1,2 Our assumption is that there is a temporal
association between the stabilization of both dopa-
mine-dependent motor symptoms and preserved stria-
tal DaT binding.
The study also provides several perspectives on the
pattern of disease progression in the various striatal
regions in these patients. We have shown that even in
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affected than the caudate. The explanation for this
phenomenon might be related to the topography of ni-
grostriatal connections. Postmortem studies of the sub-
stantia nigra in PD indicate that neuronal loss tends to
be the greatest in the ventrolateral tier, followed by
the medial ventral and dorsal tiers.12,13 Cytoarchitec-
tonic analysis of the nigrostriatal pathways in cats and
primates indicates that the ventrolateral tier projects
mainly to the putamen and to the posterior sectors of
the caudate, whereas the medial substantia nigra pre-
dominantly projects to the rostral (anterior) part of
the caudate.14–17 Measurement of dopamine loss in
brains of patients with PD showed severe reduction of
dopamine levels in the putamen, while in the caudate,
the only subdivision with severe dopamine reduction
was in its most dorsal rostral part.18
Interestingly, asymmetry of DaT ligand uptake
between the ipsilateral and contralateral sides of the
caudate and putamen was still maintained many years
after motor symptom onset, although less striking
than known in early disease. This finding is in accord-
ance with anatomic, clinical, and functional imaging
studies of asymmetry in PD.19 The clinical and imag-
ing data imply that by the time the disease progresses,
the less affected side ‘‘catches up’’ with the more
affected side. A possible explanation is that there is
slowing of dopamine neuronal loss at later stages in
the initially more affected side, rather than an acceler-
ation of degeneration in the contralateral side. Lack of
correlation between asymmetry index and ligand
uptake is probably due to the reduced clinical side dif-
ference over the years or to the relatively small sample
size.
One of the limitations of the study was that for ethi-
cal reasons, study design did not control for concur-
rent anti-PD medications received by the patients. This
may theoretically increase striatal [123I]-FP-CIT bind-
ing and create an apparent floor effect. Moreover, as
FP-CIT also binds to serotonin transporters, the pres-
ervation of tracer uptake in our patients might reflect,
in part, serotonergic neuronal function. However, the
pattern of [123I]-FP-CIT binding in our patients is sim-
ilar to that observed in early stages. Also, the concen-
trations of serotonin transporters in the basal ganglia
are low. Therefore, we believe that FP-CIT binding is
this group of patients represents the function of dopa-
minergic and not serotonergic neurons. Another
obvious limitation was that only a single SPECT imag-
ing was performed. Indeed, these results warrant fur-
ther studies with longitudinal serial imaging in the
same patients.
In conclusion, our study demonstrates that the neu-
rodegenerative mechanism that causes loss of nigro-
striatal dopaminergic neurons is not totally
destructive. These findings are encouraging, as they
may imply that the nigrostriatal system is still partially
viable in some parts of the striatum even after a long
course of the disease. This may have significant impli-
cations for future therapeutic strategies in PD, espe-
cially those targeting the nigrostriatal system.
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ABSTRACT
Motor fluctuations in Parkinson’s disease (PD) can be reduced
by intraduodenal infusion of levodopa-carbidopa (DuodopaVR )
via percutaneous endoscopic gastrojejunostomy (PEG). We
applied the transcutaneous soft-tissue anchored titanium port
(T-port) in 15 PD patients with motor fluctuations; 7 Duodopa-
naive (non-PEG), and 8 previously receiving Duodopa (former-
PEG). Motor scores (UPDRS-III) and quality of life (QOL, PDQ-
8) were assessed at baseline and 6 month follow-up. Six
patients had local irritation shortly after implantation, persist-
ing in one patient at 6 month follow-up, which led to explanta-
tion. After having finished the protocol, four T-ports were
explanted in total. UPDRS-III and PDQ-8 scores improved
moderately in the non-PEG patients, but remained similar in
the former-PEG users. Two former-PEG users developed poly-
neuropathy. No obstructions, retractions, or leakages
occurred. Technical and hygienic properties of the T-port were
preferred by most patients. The T-port seems to be suitable
for most PD patients qualifying for Duodopa therapy, although
local infection may lead to explantation during longer-term fol-
low-up. VC 2010 Movement Disorder Society
Key Words: Parkinson’s disease; duodopa; T-port
Most patients with Parkinson’s disease (PD) develop
clinical response fluctuations and dyskinesias during
the course of the disease.1 These complications can be
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reduced by achieving constant plasma concentrations
of levodopa, using f.i. intraduodenal infusion of levo-
dopa-carbidopa gel (DuodopaVR ).2 Duodopa has been
accepted as an effective treatment of fluctuating levo-
dopa-responsive PD patients irrespective of optimal
oral medication,3–5 although technical problems with
the percutaneous endoscopic gastrojejunostomy (PEG)
system frequently occur.4,6 A soft tissue-anchored
transcutaneous titanium port, the T-port (Fig. 1), has
been introduced recently as an alternative to the for-
mer PEG.7 The T-port allows ingrowth of subcutane-
ous tissue, resulting in good fixation and possibly a
barrier for local infection.8 Apart from the fixation
into the abdominal wall and the attached internal tube
to the duodenum, the T-port may overcome the aes-
thetic hurdles for patients to start with Duodopa.7
The aim of the current study was to extend the
experiences with the third generation T-port for Duo-
dopa infusion in a larger sample of advanced PD
patients. To assess whether use of the T-port would
reduce frequent tubing and connector related compli-
cations of the current PEG system, PD patients already
treated with Duodopa through a PEG system (‘‘for-
mer-PEG’’) were compared with PD patients that were
Duodopa naı̈ve (‘‘non-PEG’’). Second, the effects of
Duodopa treatment using the T-port on motor score
and quality of life (QOL) were assessed.
Patients (or Subjects) Methods
Patients
Fifteen patients with idiopathic PD (eight former-
PEG, seven non-PEG) with motor fluctuations and/or
dyskinesias, not optimally treated with oral drugs,
participated in this study. The patient characteristics
are described in Table 1. PD was diagnosed according
to the UK PD Society Brain Bank criteria and was
confirmed at the UMCG Neurology Movement Disor-
der clinic (KLL and TL). Non-PEG patients were
included if they showed a satisfying clinical response
to Duodopa during the test phase. Inclusion took
place from September 2007 until December 2008,
whereas the final visit of the last patient was in May
2009. This study was approved by the Medical Ethical
Committee of the University Medical Center Gro-
ningen. All participants signed informed consent.
Design
Prior to inclusion all patients received Duodopa
treatment via a naso-gastrojejunal tube; former-PEG
patients to allow the PEG opening to heal, non-PEG
patients to test the clinical response on Duodopa. The
baseline visit was scheduled after the wound was
healed in former-PEG patients. The non-PEG baseline
visit took place before the test phase (i.e. while still on
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oral medication). Within 1 month from baseline, the
T-port was implanted. Duodopa administration was
started immediately after implantation.
T-port Implantation
Interventional radiologists (RN: first two patients;
TP: the others) performed all T-port (generation III)
implantations and radiological gastrostomies under
local anesthesia. Before implantation, patients received
1 g cefazoline intravenously. The transverse colon was
radiographically visualized with contrast medium. The
stomach was inflated with air via a nasogastric tube.
Under local anesthesia and fluoroscopic guidance, the
stomach was percutaneously punctured with an 18-
gauge needle. A T-fastener (William Cook Europe,
Bjaeverskov, Denmark) was positioned inside the
stomach. A 4-French (F) catheter was placed at the
ligament of Treitz, replaced with a stiff guide wire
and the percutaneous tract dilated to 10-F. A 10-F,
60-cm-long polyurethane tube (PBN Medicals, Sten-
lose, Denmark) with a metallic cone at the proximal
and a pig tail curl at the distal end was inserted over
the stiff guide wire with its tip beyond the ligament of
Treitz. A subcutaneous pocket was created with a skin
incision where the perforated flange of the T-port was
placed. The intestinal tube was fixated inside the T-
port. The string/needle was pulled out beside the port
and fixated on gauze, allowing the T-fastener to fix
the anterior wall of the stomach against the abdomi-
nal wall. The string was cut after 10–14 days. Postop-
erative care involved pain-relief medication,
rebandaging as needed and cleaning the T-port entry-
zone with water, whereas debris was removed if
necessary.
Assessments
Adverse events were documented. Tolerability was
defined as the number of subjects who completed the
6 months protocol. Motor scores and QOL were
assessed using part III of the Unified Parkinson’s Dis-
ease Rating Scale (UPDRS-III) and the PDQ-8,9
respectively. Mean scores with SD were calculated for
baseline and 6 months follow-up visits. A paired t-test
was used to compare means between groups.
Results
T-port Complications
T-port implantations were without technical prob-
lems and early wound recovery was uneventful.
Shortly after implantation, six patients had local irrita-
tion around the port that is, more pronounced red-
ness, pain and/or secretion. This resolved
spontaneously or after application of Fucidin crème
within 1 month post-implantation. One patient (non-
PEG) had persisting low grade secretion, worsening
over time. Bacterial culture revealed Pseudomonas
FIG. 1. A. Parts of the generation III T-port. B. T-port implanted in a patient with PD. The plastic tube is connected to a Duodopa pump and to a
tube through the stomach wall with the tip in the small intestine.
TABLE 1. Demographics
Former-PEG Non-PEG
Age 61 (14), 33–76 62 (9), 49–78
Disease duration 17.4 (7.5), 4–26 13.1 (4.7), 6–20
Men 5 5
women 3 2
UPDRS-III (baseline) 27.3 (15.7), 7–54 31.3 (12.4), 17–46
PDQ-8 (baseline) 9.6 (6.1), 0–17 10.7 (3.1), 6–15
Duodopa dose visit 6 1999 (804), 1047–3040 1702 (199), 1432–2022
Where applicable, mean, (standard deviation, SD) and range are depicted.
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contamination of the T-port. No kinking, retractions,
blocking, and leaking occurred.
Non-T-port Related Complications
Two former-PEG patients developed an axonal sen-
sory polyneuropathy (combined with motor symptoms
as well in one patient), confirmed by EMG. Labora-
tory controls revealed borderline Vitamin B12 levels.
Both patients had received Duodopa for < 1 year,
one patient receiving 3040 mg/day (24 hour infu-
sion), the other 1892 mg/day (16 hour infusion).
Duodopa dose was not changed after switching from
PEG to T-port. Complaints in both patients improved
when Duodopa dose was lowered and vitamin B12
was supplemented.
Clinical Assessments
Seven out of eight former-PEG considered the T-
port system as good to very good. One patient had
progressive gait disturbances and sensory axonal poly-
neuropathy. The other patient who developed poly-
neuropathy was content regarding the T-port system.
Seven out of eight had experienced multiple PEG-
related problems previously, like obstruction (n ¼ 3),
leakage (n ¼ 5), dislocation (n ¼ 4), and infection (n
¼ 2), probably explaining the improved motor fluctua-
tions after T-port implantation. The T-port was con-
sidered as a clear improvement, compared to the
former PEG system, in terms of handling, aesthetical
aspects and mechanical complications. Four of seven
non-PEG patients considered the motor response to be
excellent. Two patients were moderately happy, but
both suffered from concomitant depression and one
missed the oral dopamine agonist, which had been
stopped once Duodopa was started. Another patient
experienced progression of pre-existent cognitive
impairments.
Mean (SD) UPDRS-III and PDQ-8 scores at baseline
and 6 months follow-up were respectively 25.0 (15.5)
and 21.9 (11.5), 9.1 (6.5) and 8.3 (5.4) for former-
PEG and 31.3 (12.4) and 22.6 (9.8), 10.7 (3.1) and
7.1 (4.9) for non-PEG patients. Baseline and 6 month
UPDRS-III and PDQ-8 scores were similar for former-
PEG (respectively t ¼ 0.54, P ¼ 0.6 and t ¼ 0.089, P
¼ 0.41). Non-PEG patients showed a trend towards
improvement on both scores at 6 months (UPDRS-III:
t ¼ 2.16, P ¼ 0.07 and PDQ-8: t ¼ 2.12, P ¼ 0.08).
When tested one-tailed, these results are significant on
a P < 0.05 level.
Discussion
The T-port system appears to be a satisfying device
in the majority of PD patients qualifying for Duodopa
therapy. During the 6 month follow-up after implanta-
tion, the T-port was well tolerated in 14 of 15
patients. However, due to infection, four T-ports were
explanted after having finished the protocol. So within
the first 6 months, the tolerability of the T-port was
100%, which decreased to 73% after longer duration
follow-up (>1 year). In one patient the infection was
clearly due to a lack of hygiene. Other reasons for dis-
satisfaction were concomitant depression in two
patients and progression of pre-existent cognitive
impairments in one other patient. However, both were
unrelated to the T-port device.
The total lack of obstructions, kinking, retractions,
or leakage is an important improvement compared to
the former PEG-systems. Newer PEG systems, f.i. the
FREKA PEG tube, perform much better, becoming
more comparable to the T-port. Longer follow-up is
needed to get complete insight in the long-term toler-
ability of the T-port.
Apart from technical properties, patients preferred
the aesthetic properties of the T-port. The generation
III T-port is considerably better tolerated than the ear-
lier generation T-ports.7
Non-T-port related adverse events included axonal
polyneuropathy, not directly linked to a significant
vitamin B12 deficiency, although suppletion seemed to
improve patients’ complaints. A recent study described
that a high proportion of PD patients receiving levo-
dopa therapy for a long time, at higher doses may de-
velop an axonal neuropathy.10
Motor Response and QOL
Motor scores improved moderately in non-PEG,
confirming earlier reports about positive effects of
Duodopa on PD motor symptoms.2–4,11,12 Even
though our Duodopa-naive group consisted of a very
small number of patients, one-tailed statistical testing
revealed a significant improvement of motor functions
over 6 months time.
Additionally, QOL improved in non-PEG, as meas-
ured with the PDQ-8. Although we did not perform
extensive cognitive and affective testing, this screening
test indicates overall wellbeing, related to PD.9 A
recent study investigating effects of Duodopa on non-
motor symptoms and quality of life showed similar
results, with improvement on PDQ-8 scores after 6
months follow-up.11
Conclusions
The T-port system seems to be a suitable alternative
to PEG tubes for PD patients who qualify for Duo-
dopa therapy. However, the explantations during lon-
ger follow-up, due to local infections, indicate that the
T-port is not the solution for all patients with
Movement Disorders, Vol. 26, No. 2, 2011 333
T - P O R T A N D D U O D O P A I N P A R K I N S O N ’ S D I S E A S E
Duodopa. Longer follow-up is needed to determine
the definite position of the T-port in the treatment of
PD.
References
1. Marsden CD. Problems with long-term levodopa therapy for Par-
kinson’s disease. Clin Neuropharmacol 1994;17 Suppl 2:S32–S44.
2. Bredberg E, Nilsson D, Johansson K, et al. Intraduodenal infusion
of a water-based levodopa dispersion for optimisation of the ther-
apeutic effect in severe Parkinson’s disease. Eur J Clin Pharmacol
1993;45:117–122.
3. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infu-
sion in Parkinson’s disease--long-term experience. Acta Neurol
Scand 2001;104:343–348.
4. Nyholm D, Lewander T, Johansson A, et al. Enteral levodopa/
carbidopa infusion in advanced Parkinson disease: long-term ex-
posure. Clin Neuropharmacol 2008;31:63–73.
5. Odin P, Wolters E, Antonini A. Continuous dopaminergic stimu-
lation achieved by duodenal levodopa infusion. Neurol Sci 2008;
29 Suppl 5:S387–S388.
6. Devos D. Patient profile, indications, efficacy and safety of duode-
nal levodopa infusion in advanced Parkinson’s disease. Mov Dis-
ord 2009;24:993–1000.
7. Nyman R, Lundgren D, Nyholm D. Soft tissue-anchored transcu-
taneous port attached to an intestinal tube for long-term gastro-
duodenal infusion of levodopa/carbidopa in Parkinson disease. J
Vasc Interv Radiol 2009;20:500–505.
8. Nyman R, Eklof H, Eriksson LG, et al. Soft-tissue-anchored
transcutaneous port for long-term percutaneous transhepatic bili-
ary drainage. Cardiovasc Intervent Radiol 2005;28:53–59.
9. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the de-
velopment, validation and application of a Parkinson’s disease
quality of life questionnaire and its associated measures. J Neurol
1998;245 Suppl 1:S10–S14.
10. Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D.
Neuropathy as a potential complication of levodopa use in Par-
kinson’s disease. Mov Disord 2008;23:1850–1859.
11. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levo-
dopa infusion in Parkinson’s disease: a pilot multicenter study of
effects on nonmotor symptoms and quality of life. Mov Disord
2009;24:1468–1474.
12. Raudino F, Garavaglia P, Pianezzola C, et al. Long-term experi-
ence with continuous duodenal levodopa-carbidopa infusion
(Duodopa): report of six patients. Neurol Sci 2009;30:85–86.
Nonlinear Decline of Mini-Mental
State Examination in Parkinson’s
Disease
Dag Aarsland, MD, PhD,1,2* Graciela Muniz, PhD,3
and Fiona Matthews, PhD3
1Centre for Age-Related Medicine, Division of Psychiatry, Stavanger
University Hospital, Stavanger, Norway; 2Section of Clincal MEdcin,
Akershus University Hospital, University of Oslo, Oslo, Norway;
3Medical Research Council Biostatistics Unit, Cambridge, United
Kingdom
ABSTRACT
The trajectory of cognitive functioning in patients with Parkin-
son’s disease (PD) is not known. We used a random change
point model to study the individual cognitive trajectory for up
to 15 years in a prevalence sample of 238 PD patients, and
used the mini-mental state examination (MMSE) to assess the
longitudinal cognitive course. We observed that the rate of
global cognitive decline was nonlinear. Following a relatively
stable period, an inflection point was identified, after which
the rate of decline gained momentum with an annual decline
of 2.8 points on the MMSE. The course was similar in men
and women. This inflection point was estimated to occur 13.3
years (95% credible interval 11.8, 13.6) after the diagnosis of
PD; however, there were wide interindividual variations in the
time from onset of PD to the inflection point. VC 2010 Move-
ment Disorder Society
Key Words: Parkinson’s disease; cognitive impairment;
course; nonlinear
Significant cognitive decline can be detected already
during the first 3 years after the diagnosis of Parkin-
son’s disease (PD), although some patients remain sta-
ble.1,2 In one of the few studies assessing long-term
cognitive decline,3 marked interindividual variation
was observed, and interestingly, there seemed to be a
time-dependent effect, i.e., patients showed a much
more rapid decline in the period after dementia was
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diagnosed compared with the predementia period.
However, the statistical method used in the study did
not allow for the identification of the onset of this
acceleration in the sample nor the trajectory of
decline.
A nonlinear decline has also been reported in elderly
people developing Alzheimer’s disease, where a sharp
‘‘inflection point’’ seems to exist, after which the rate
of cognitive decline starts to increase.4 To our knowl-
edge, the trajectory of cognitive decline in PD has not
yet been explored in detail. Such information is impor-
tant to predict clinical course in individual patients
and to inform future clinical trials. Therefore, by rean-
alyzing data from a long-term community-based prev-
alence cohort, we wanted to test the hypothesis that
global cognitive decline is not linear in PD, and to
explore whether an inflection point for global cogni-
tive decline can be identified. In addition, as there is
evidence of marked heterogeneity in the time from
onset of PD to dementia,5 we wanted to investigate
how the time from onset PD to such an inflection
point would vary between patients.
Patients and Methods
Patients were drawn from a population-based preva-
lence study conducted in Rogaland County, Western
Norway, in 1993. Details on patient recruitment have
been previously reported.6 In brief, from a population
base of 220,000, 400 subjects were identified
through search of hospital files and information
obtained from all available sources in the community
and evaluated clinically by experienced movement dis-
orders specialists. Two hundred forty-five of the sub-
jects were diagnosed with PD according to research
criteria, and 238 (51% women) fulfilled the PD diag-
nosis at subsequent assessments and consented to par-
ticipate in a prospective longitudinal clinical
observation study of PD. A subgroup of these patients
has come to autopsy and all had their clinical PD di-
agnosis confirmed neuropathologically.7
The cohort was followed prospectively for up to 12
years. Patients were examined at baseline and at fol-
low-up assessments after 4 and 8 years, and thereafter
annually. Subjects not able to be transported to the
outpatient clinic were examined at their homes or
nursing homes. At each visit, standardized rating
scales of motor, psychiatric, and cognitive symptoms
were administered, as previously described.3 At all vis-
its, global cognition was assessed using the mini-men-
tal state examination (MMSE),8 which was used as
the measure of global cognitive function in this study.
Although this scale was designed to measure cognition
in Alzheimer’s disease and is not the best method to
assess cognitive impairment in PD,9 it has shown to be
sensitive to decline in PD.3
Ethics
The study was approved by the Regional Committee
for Medical Research Ethics, Western Norway, and
patients provided written informed consent.
Statistics
As the aim of our investigation was to examine the
hypothesis of nonlinear change in cognition in PD, we
fitted a series of random effects models in which
MMSE scores were modeled as a function of duration
of disease. First, we fitted a model in which MMSE
scores were described following a linear trajectory;
second, we fitted a model following an accelerating
trajectory. Third, we considered a model consisting of
two linear phases that meet at a change point. This
change point indicates the onset of change in rate of
decline. By modeling the change point as a random
effect, we obtained an estimate of a change point for a
reference individual [man diagnosed with PD at age
65, with 95% credible interval (CI)] in addition to
estimates of the change point of each individual in the
sample examined. Further estimates of interest
obtained from the model describe cognitive perform-
ance at 9 years after PD diagnosis and annual rate of
decline before and after the onset of change in rate of
decline. All models were adjusted for possible differen-
ces by gender and age at PD diagnosis. Models were
fitted in a Bayesian framework using WinBUGS10
assuming a hierarchical structure. WinBUGS uses
Markov Chain Monte Carlo methods to produce esti-
mates of model parameters. Vague prior distributions
were considered. To assess the dependence of results
to the choice of prior distributions, sensitivity analyses
were conducted varying the prior distributions consid-
ered in the model. Results from these sensitivity analy-
ses confirmed the robustness of results reported.
Missing data were assumed to be missing at random.
Models were compared using the deviance informa-
tion criteria (DIC),12 which is a generalization of
Akaike’s information criteria.13 Models with lower
DIC are best supported by the data.
FIG. 1. Estimated mean MMSE trajectory.
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Results
At baseline, mean (SD) age was 65.0(9.8), duration of
disease 9.2(5.7), MMSE score 24.7(6.0), UPDRS III
28.5(15.8), and Hoehn & Yahr stage was 2.9(1.1)
(range 1–5). After 4 years, 128 completed MMSE and
79 after 8 years. In further waves conducted annually,
37, 30, and 26 patients completed MMSE. The vast ma-
jority of dropouts were due to death and some due to
inability to perform the MMSE, whereas less than 10%
were due to refusals. At each wave, individuals who
dropped out of the study were older at diagnosis than
those who remained in the study (t tests, P < 0.001).
No differences were found in age at diagnosis between
dropouts and nondropouts (t tests, P > 0.05).
DIC values from the linear, quadratic, and random
change point models were 3337.52, 3072.47, and
2681.04, respectively. These values indicate that the
random change point model fitted the data best and
supported the hypothesis that the decline was nonlin-
ear (Fig. 1). Results from the random change point
model fitted indicate that after the diagnosis of PD, a
period with a slow rate of decline [0.09 (SD ¼ 0.07)]
points per year was observed (Table 1). This initial
stable period was followed by a period with a much
more rapid decline, 2.8 (SD ¼ 0.3) points per year.
The decline was similar in men and women. An inflec-
tion point was found, which was estimated to occur
13.3 years (95% CI 11.8, 13.6) after the diagnosis of
PD, with a wide interindividual variation (Fig. 2).
Results were similar when reanalyzed without patients
with dementia at baseline (results not shown).
Discussion
We studied the trajectory of global cognitive decline
as measured with a global cognitive rating scale in a
prevalence sample of PD patients. The cohort was fol-
lowed for up to 12 years after the baseline assessment.
We observed that the rate of global cognitive decline
was nonlinear. Following a relatively stable period, an
inflection point was identified, after which the rate of
decline gained momentum with an annual decline of
2.8 points. Thus, the main hypothesis that global cog-
nitive decline in PD is not linear was confirmed, and
consistent with a cross-sectional study suggesting that
transition to dementia in PD is due to the addition of
cortical to subcortical deficits.14 The inflection point
was estimated to occur 13 years after diagnosis of PD.
There were wide interindividual variations in the dura-
tion to the inflection point.
One of the limitations of our study is that the long
interval between testing during the first 8 years lead to
a high dropout. Also, as only global cognition was
measured, differential trajectory of decline in various
cognitive domains, as previously reported in AD4
could not be assessed. As MMSE is less sensitive in
the earliest disease stages, this might have contributed
to the accelerated decline. Another limitation is that
this was a prevalence sample, i.e., baseline assessment
was performed mean 9 years after onset/diagnosis of
PD, with wide variations, i.e., some patients were
included immediately after onset of disease, whereas
others had had PD for up to 20 years at inclusion.
One effect of this design was that cognitive perform-
ance was variable at inclusion, with some patients
being demented already at inclusion. However, the
majority of those with dementia at baseline did not
survive to the first follow-up assessment, but some
patients might already have passed the inflection point
at inclusion. It is nevertheless possible that an
increased rate of decline at more cognitively impaired
stages, as has been shown in Alzheimer’s disease15
might have contributed to our findings.
In addition, we have previously demonstrated that
the time to dementia diagnosis varies remarkably in
PD, some developing dementia with the first 2 to 3
years after diagnosis, whereas others remain nonde-
mented for decades before developing dementia.5 Our
data suggest that this variation is primarily due to the
TABLE 1. Estimates of the MMSE scores and rate of
decline according to age and gender using the random
change point model
Fixed effects Mean (SD)
95% Credible
interval
Cognitive scores 9 yr
after diagnosis
27.1 (0.03) 26.4, 27.8
Gender (0 ¼ M, 1 ¼ F) 0.4 (0.44) 0.4, 1.3
Age at diagnosis 0.1 (0.03) 0.2, 0.09
Annual rate of decline
before change point
0.09 (0.07) 0.2, 0.05
Gender (0 ¼ M, 1 ¼ F) 0.04 (0.09) 0.1, 0.2
Age at diagnosis 0.005 (0.005) 0.004, 0.02
Annual rate of decline
after change point
2.8 (0.3) 3.4, 2.3
Gender (0 ¼ M, 1 ¼ F) 0.09 (0.3) 0.6, 0.8
Age at diagnosis 0.07 (0.01) 0.1, 0.04
Change point 13.3 (0.8) 11.8, 13.6
FIG. 2. Histogram of estimated patient-specific change points.
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time to the inflection point, which is followed by a
rapid decline rather than a variation in the slope of
decline. Further methodological work is required to
allow for the investigation of factors that may delay
the onset of a change in rate of decline.
Our findings of nonlinear cognitive decline have
relevance for patient information about prognosis, as
well as for clinical trials attempting to delay the onset
of dementia or reduce the rate of cognitive decline.
Future studies should also include patients at time of
diagnosis, and tests assessing various cognitive
domains should be administered, to explore whether
such an inflection point occurs for all domains and at
the same or different time points.
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ABSTRACT
In a recent GCH1 mutation screen, an 18-bp deletion was
identified within the proximal promoter in two patients with
early-onset Parkinson’s disease. The mutation removes cAMP
response element critical for adequate GTP cyclohydrolase I
activity in selected cell types, including dopaminergic neurons,
but its biological significance was unclear as it was also
detected in one control individual. We present an 11-year-old
boy with infantile-onset severe dystonic encephalopathy with-
out hyperphenylalaninemia whom we found compound hetero-
zygous for the same promoter GCH1 deletion and another
common missense mutation associated with classical dopa-
responsive dystonia. Extensive diagnostic work up excluded
other causes of dystonia, and comprehensive mutation scan
did not reveal any additional GCH1 sequence variations, sup-
porting the association between the promoter deletion and
disease phenotype. VC 2010 Movement Disorder Society
Key Words: GTP cyclohydrolase 1 deficiency; dopa-re-
sponsive dystonia; GCH1; promoter; dystonic
encephalopathy
Introduction
GTP cyclohydrolase I (GCH1; EC 3.5.4.16) cata-
lyzes the first step in the biosynthesis of tetrahydro-
biopterin (BH4), a cofactor of phenylalanine, tyrosine
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and tryptophan hydroxylases, all NO synthase iso-
forms, and glyceryl-ether mono-oxygenase.1 GCH1
deficiency manifests with a spectrum of neurological
deficits,2 including dystonic features attributable to
predominant dopamine depletion in the striatum.3 The
clinical presentation depends upon the gene dosage
(one vs two mutant alleles), residual normal function
and possible dominant negative effects of the mutated
allele, and potential modifier factors (e.g., estradiol-de-
pendent transcription enhancement4). The most com-
mon syndrome is that of dopa-reponsive dystonia
(DRD; MIM# 128230), an autosomal dominant local-
ized dystonia characterized by excellent response to
low-dose levodopa.5 Mutations of both GCH1 alleles
produce a spectrum of autosomal recessive dystonic
encephalopathies with or without hyperphenylalanine-
mia (HPA).6,7 Comprehensive mutation scans in
GCH1-deficient patients revealed more than 100 dis-
tinct mutations, none of which localized to the GCH1
promoter.8,9
Due to some overlap between DRD and early-onset
Parkinson’s disease (EOPD) a large cohort of EOPD
patients were screened for GCH1 mutations with gen-
erally negative results except for a heterozygous 18-bp
proximal promoter deletion detected in two EOPD
PRKN-negative patients without dystonia.10 Although
the same deletion was found in one control individ-
ual,10 it may have functional consequences, as it
removes cAMP response element (CRE) required for
cAMP-mediated transcription critical for GCH1 activ-
ity in some cell types, including midbrain and hypo-
thalamic dopamine neurons.11
The clinical relevance of this mutation is highlighted
by our case report of an 11-year-old boy with severe
dystonic encephalopathy without HPA whom we
found compound heterozygous for the 18-bp promoter




The 11-year-old proband (III:7 in pedigree in Fig.
1), born full-term after a noneventful pregnancy and
delivery is the only child of nonconsanguineous
parents of Polish origin. In the first few months of life
he was noted for delayed psychomotor development
with axial hypotonia and dystonic posturing of the
extremities. He had poor suck and difficulty swallow-
ing, leading to relative failure to thrive. He has never
been able to walk, sit unsupported, roll over, or vol-
untarily control sphincter function. Severe dystonia of
the trunk and limbs has dominated the clinical course
beyond the infantile period. Additionally, he has
developed brisk deep tendon reflexes in both upper
and lower extremities, bilateral striatal toe imitating
extensor plantar response but without toe fanning,
thoracic scoliosis, and shortening of the right leg.
Prominent jaw dystonia has made him unable to fully
close his mouth and produce normal speech (he only
can utter a few poorly intelligible words). His parents
claim he can comprehend language well, but formal
neuropsychological testing is difficult to perform due
to profound movement impairment.
Magnetic resonance imaging (MRI) of the brain,
nerve conduction velocities and electromyography,
and ophthalmological examination were normal. Lab-
oratory studies, including blood count, routine bio-
chemistry, full plasma amino acid profiles, serum
lactate, ammonia, copper and ceruloplasmin, serum
tandem mass spectrometry, urine gas chromatography-
FIG. 1. The family pedigree.
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mass spectrometry, serum biotinidase, peripheral leu-
kocyte lysosomal enzymes, and transferrin isoforms
were all negative or normal. Specifically, plasma phe-
nylalanine levels were consistently well within a refer-
ence range (26–98 lmol/L). Lumbar puncture was not
performed due to lack of parental consent. Karyotype
was normal male (46,XY). The TOR1A assay
excluded a common c.904-906delGAG mutation re-
sponsible for early-onset primary dystonia (DYT1).
Levodopa therapy (50 mg/day), initiated based on
the results of the genetic testing (see below), has led to
moderate but clinically significant improvement. He
can close his mouth, chew, and swallow more effec-
tively, which has led to considerably better food
intake, and has started moving his limbs more vigo-
rously. However, further dose increase has been pre-
vented by emerging dyskinesia.
Family History
The patient’s mother (II:13) had an insidious onset
of walking difficulty in childhood with slowly progres-
sive dystonic posturing and hyperreflexia of the lower
limbs, bilateral pes cavus, and mild postural hand
tremor. The signs and symptoms were asymmetrical
with left predominance and relative shortening of the
left leg. MRI of the brain, ophthalmological examina-
tion, and neuropsychological assessment were all nor-
mal. She showed an excellent response to low-dose
(200 mg/day) levodopa therapy with complete resolu-
tion of neurological deficits. Her mother (I:1) and four
of her sisters (II:3, II:6, II:10, and II:11) were similarly
diagnosed with DRD and successfully treated with lev-
odopa (100–300 mg/day).
The patient’s father (II:14), aged 35, has a nonprog-
ressive spastic right hemiparesis following infantile tu-
berculous meningoencephalitis, but no indication of
dystonia or parkinsonism. His mother (I:3) died in
older age without signs or symptoms of a neurological
disease. His father (I:4), two younger sisters (II:15 and
II:16), and four daughters (III:8–11) of one of them
are reportedly healthy, though have not been available
for clinical evaluation or genetic testing.
Results
The GCH1 gene was analyzed in the proband, his
parents, and his mother’s relatives (Fig. 1) with bidir-
ectional sequencing. The analysis included all coding
exons with flanking intronic fragments, two alterna-
tive splicing isoforms of the final coding exon, 50UTR,
and circa 500 bp of the proximal promoter.
The proband (III:7) was found compound heterozy-
gous for the missense c.614T>G (V205G) mutation,
inherited from his mother (II:13), and 18-bp promoter
deletion (Fig. 2), transmitted by the father (II:14). All
symptomatic members of the mother’s family were het-
erozygous carriers of the same V205G substitution. We
also detected it in two asymptomatic individuals (one of
the mother’s sisters, and a daughter of one symptomatic
sister). The V205G mutation was previously associated
with DRD,12 and a lack of clinical impairment in the
two asymptomatic carriers may reflect either a reduced
penetrance or presymptomatic phase.
We sequenced the proximal GCH1 promoter region,
encompassing the site of the 18-bp deletion, in 100
healthy, nonconsanguineous control individuals (or
200 chromosomes), representing general adult popula-
tion of Southern Poland, and did not find any
sequence variations.
Discussion
In this report, we present evidence for the clinical
relevance of the 18-bp GCH1 promoter deletion in
humans. This mutation has recently been identified in a
heterozygous state in two patients with EOPD without
dystonia, but also in one control individual, which
made the association unclear.10 The deletion overlaps
the CRE and Sp1 consensus motifs (Fig. 2). CRE and
adjacent CCAAT-box mediate the effects of cAMP on
GCH1 expression, enabling the interaction between
CRE binding protein, CCAAT-enhancer binding pro-
tein beta, and nuclear factor-Y.13 The GCH1 expres-
sion is regulated in a tissue-specific manner with cAMP
being an enhancer in a limited number of cell types,
including midbrain and hypothalamic dopamine neu-
rons,11 adrenal medullary cells,14 and mesangial cells.15
The proband, compound heterozygous for the pro-
moter deletion and common missense mutation, pre-
sented with a phenotype largely similar to other
reported cases of severe GCH1 deficiency resulting
from mutations in both alleles.6,7 The promoter muta-
tion very likely reduces the rate of GCH1 expression in
a couple of tissues critically dependent on cAMP, such
as dopaminergic neurons, but it does not affect the pro-
tein product itself, and should not lead to enzyme
FIG. 2. The sequence of the GCH1 proximal promoter with key tran-
scriptional motifs. The deleted nucleotides are marked with shading.
CCAAT 5 CCAAT box; CRE 5 cAMP response element; Sp1 5 bind-
ing site of transcription factor Sp1; TATA 5 TATA box.
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deficiency in other cell types, explaining the lack of
HPA. Moreover, the accompanying V205G missense
mutation may confer a lower HPA risk, which is sug-
gested by the lack of HPA in a boy with a homozygous
mutation in the adjacent codon (V206A).7
The important limitation of our report is that we
were unable to measure pterin levels in the cerebrospi-
nal fluid or GCH1 activity in the patient’s cells. Such
tests are highly specialized and not readily available;
besides, we had no parental consent for lumbar punc-
ture. It should be stressed, however, that the transcrip-
tional insufficiency caused by the loss of CRE in the
promoter is likely limited to few cell populations,
which are normally inaccessible for testing in a living
person. Nevertheless, the evidence for the pathogenic
nature of the 18-bp promoter deletion is compelling:
consistent clinical presentation, mutation segregation
with the autosomal recessive phenotype, no additional
GCH1 sequence variants, extensive exclusion of alter-
native etiologies, and clear response to levodopa in
combination with the previous in vitro data on the
physiology of the GCH1 proximal promoter.13
The improvement following the administration of lev-
odopa was significant but partial, which could be attrib-
uted to at least three factors: (1) we have not been able
to start the patient on concomitant BH4 therapy (as rec-
ommended by several authors)7,14 because of high cost
and administrative barriers (lack of drug registration
for this indication), (2) we could not use levodopa in
doses higher than 50 mg/day due to poorly tolerated
dyskinesia, and (3) the longstanding dopaminergic defi-
cit in the developing brain may have led to persistent
and potentially irreversible neuronal dysfunction.
Although this case suggests the 18-bp promoter de-
letion may become symptomatic in combination with
a missense mutation of the other allele, it remains to
be determined if it can also be pathogenic in heterozy-
gous carriers, and, specifically, whether it can cause
Parkinson’s disease (PD). At age 35, the patient’s fa-
ther has no dystonic or parkinsonian features, and
nonprogressive hemiparesis can well be explained by
infantile neuroinfection. However, we monitor his
neurological status continuously, as the two reported
men with EOPD and the same mutation were aged 33
and 36 at onset.10
The mechanism whereby theGCH1 promoter mutation
could increase the PD risk or lead to the development of
PD-like phenotypes will remain a matter of speculation
until functional studies are performed on promoter knock-
out cell line and animal models. It has recently been
hypothesized that PD and DRD could be differentiated by
complementary dopamine deficiency patterns in the stria-
tum with predominant dopamine loss in the matrix and
striosome compartments in PD and DRD, respectively.16
In DRD, neuropathological studies17 have revealed loss of
tyrosine hydroxylase in nigrostriatal neurons but, unlike
in PD, without signs of their degeneration. The GCH1
promoter mutation may result in relative dopamine defi-
ciency in certain neuronal subpopulations, and thus create
environment for development of parkinsonism in response
to secondary insults.
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ABSTRACT
Action myoclonus frequently remains the primary cause of dis-
ability in Unverricht-Lundborg disease (EPM1) patients. Phar-
macological treatment of myoclonus in these patients
continues to be challenging; indeed conventional AEDs may
be poorly effective in monotherapy or even in combination.
We carried out a pilot, open-label trial of add-on zonisamide
(ZNS) in patients with EPM1. Twelve EPM1 patients with epi-
lepsy and action myoclonus were included in the study. Oral
ZNS was gradually titrated until the target dose of 6 mg/Kg/
day. Unified Myoclonus Rating Scale was obtained in each
subject before and after ZNS add-on. A significant reduction
of myoclonus severity was reached after ZNS introduction.
ZNS was generally well tolerated and only two patients with-
drew due to mild adverse effects. Our trial suggests that ZNS
may be a valuable therapeutic option in EPM1 patients.
VC 2010 Movement Disorder Society
Key Words: zonisamide; Unverricht-Lundborg disease;
epilepsy; myoclonus
Action myoclonus may be due to multiple etiological
factors enhancing motor cortex excitability. It is often
intractable and related to severe functional disability.1
Unverricht-Lundborg disease (EPM1) is the most com-
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mon form of progressive myoclonus epilepsies. Symp-
toms stabilize in adulthood but action myoclonus
frequently remains the primary cause of disability in
affected.2
Zonisamide (ZNS), a new-generation antiepileptic
drug (AED) with broad spectrum and multiple poten-
tial mechanisms, is licensed for adjunctive treatment
of partial seizures in adults.3 Only few reports suggest
the potential efficacy of ZNS in patients with myoclo-
nus, but systematic studies on a specific type of pro-
gressive myoclonus epilepsy (PME) have not been
performed yet.4–6
We carried out a pragmatic, pilot, open-label trial
to evaluate the tolerability and the antimyoclonic effi-
cacy of ZNS in patients with EPM1.
Patients and Methods
We included 12 patients with homozygous expan-
sion of CSTB promoter and chronic (without remis-
sion for at least 1 year), refractory (partially
responsive or unresponsive to at least two conven-
tional antimyoclonic AEDs) action myoclonus, con-
firmed by electrophysiological investigations (Table 1).
All patients were asked to sign a written informed
consent, and the local ethical committees approved the
study. Twelve patients (7 men) aged from 22 to 70
years (mean: 42.6 6 13.6) were recruited. Duration of
myoclonus ranged from 12 to 60 years (mean: 30.8 6
12.3). Six patients also showed negative myoclonus.
All patients but one was on polytherapy (Table 1).
ZNS was orally administered at a starting dose of 25
mg twice/day for 1 week and up-titrated to 50 mg
twice/day for the next 2 weeks, followed by incre-
ments of 50 mg twice/day each week until to the tar-
get dose of 6 mg/Kg/day. Titration phase ranged 4
to 6 weeks. To assess myoclonus severity, all patients
underwent Unified Myoclonus Rating Scale (UMRS)7
before ZNS add-on and 2 weeks after the end of titra-
tion phase. Dosage of concomitant AEDs remained
constant for at least 3 months before the beginning to
the end of the trial and their plasma levels were moni-
tored monthly. Mean pretreatment and post-treatment
scores for each UMRS section were compared. Statisti-
cal analyses were carried out by using v2-test, Wil-
coxon matched-pairs test, and Spearmen test.
Results
All patients completed the trial. The duration of the
study ranged from 6 to 8 weeks. The ZNS reached
dose was between 300 and 500 mg/day (mean: 391.6
6 66.8). ZNS add-on was associated with clinical
improvement of myoclonus and lowering of mean
scores on all UMRS sections except Section 6 (physi-
cian’s assessment of disability) (P < 0.05; Fig. 1). No
correlation between duration of disease and ZNS
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response was found. UMRS scores after ZNS add-on
did not statistically differ in patients with and without
levetiracetam (LEV). No change in the plasma level of
concomitant AEDs occurred during the trial. ZNS was
well tolerated by all the subjects except from 2
patients who exhibited drowsiness (10, 11) and
another one (1) who reported paresthesias and irrita-
bility (Table 1). However, these adverse effects were
of mild or moderate severity and discontinuation of
the drug is not needed. Two subjects (2,3) withdrew
ZNS a few days after final UMRS evaluation due to
loss of efficacy. The remaining 10 subjects were clini-
cally revaluated at 3-months intervals (mean follow-
up: 23 6 9.3 months; range 6–32) and all are still on
ZNS, exhibiting sustained antimyoclonic effect.
Discussion
So far, therapy of epilepsy and action myoclonus in
EPM1 patients continues to be challenging. Conven-
tional AEDs may be poorly effective in monotherapy
or even in combination.1 Systematic controlled studies
about the effects of new AEDs on myoclonus in PMEs
patients are lacking. An open-label study of 13 EPM1
patients demonstrated the effectiveness of LEV in
reducing myoclonus severity, especially in younger
subjects.8 Topiramate may also be useful but its effec-
tiveness is not permanent possibly due to the develop-
ment of drug tolerance.9 Lamotrigine may even
aggravate myoclonus in EPM1 patients.10 The only
existing open-label trial on PMEs patients receiving
adjunctive ZNS (6 mg/kg/day) therapy for 16 weeks
showed a 50% and a 75% reduction of ‘‘myoclonic
seizures’’ in 36 and 21% patients.6 This study
included 7 EPM1 patients, but the efficacy of ZNS on
this specific group of patients was not reported. In
addiction, in our study, we used UMRS, the most
appropriate statistically validated clinical instrument
to assess myoclonus severity.7 After the end of trial,
mean post-treatment scores were significantly lowered
for all UMRS section except for global disability score
(Section 6). However, the latter is a subjective measure
prone to possible bias in an open-label trial particu-
larly in such severely compromised patients with a













1/F/25 24 VPA 1750 300 6 Paresthesias, irritability
2/M/49 38 VPA 1000, CLZ 6, ACZ 250 400 7 –
3/F/37 29 VPA 1500, LEV 3500, PB 100 500 8 –
4/F/43 31 LEV 1000, VPA 1000 400 7 –
5/M/39 30 VPA 750, ACZ 250, PB 100, CLZ 4, LEV 4000 400 7 –
6/M/52 31 VPA 2000, CLZ, PB 400 7 –
7/F/52 33 VPA 1500, CLZ, PB 400 7 –
8/M/27 12 VPA 1000 400 7 –
9/M/48 33 LEV 2000, CLZ 5, VPA 1200, PRM 250 400 7 –
10/M/48 36 VPA 1800, LEV 3500, PB 100, CLZ 6 300 6 Drowsiness
11/F/22 13 LEV 4500, CLZ 18, CLZ 6, PB 100 300 6 Drowsiness
12/M/70 60 CLZ 6, PB100 500 8 –
VPA, valproate; CLZ, clonazepam; ACZ, acetazolamide; LEV, levetiracetam; PB, phenobarbital; PRM, primidone.
FIG. 1. Mean UMRS scores before and after the trial compared by using the Wilcoxon signed rank test. ZNS treatment was associated with a sig-
nificant reduction in the Sections 1–5 of UMRS.
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long history of disease. ZNS was generally well toler-
ated and only 2 patients withdrew at follow-up due to
mild adverse effects. Moreover, only 2 patients
showed attenuation of ZNS efficacy at follow-up. This
is in agreement with the results of a previous work
reporting that ZNS may decrease its antimyoclonic ef-
ficacy over time due to the natural worsening of the
disease or tolerance development.5
In a long-term follow-up study, Magaudda et al.2
found that EPM1 exhibits a self-limiting progression
with symptom stabilization after 10 years of disease.
In our study, we did not find any significant correla-
tion between the duration of disease and ZNS
response. Therefore, we can suppose that the loss of
ZNS antimyoclonic effect observed in 2 of our EPM1
subjects, may be due to tolerance development rather
than the natural worsening of disease. Moreover, ZNS
significantly reduced myoclonus severity even in
patients were already on LEV.
This study includes the largest series of EPM1
patients on ZNS so far reported. Our data suggest
that this drug may be a valuable therapeutic option in
these patients. Prospective randomized, double-blind
studies are needed to confirm these data.
Acknowledgment: We are grateful to Dr. Lilla Bonanno for statistical
analyses.
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ABSTRACT
Since a postinfectious or autoimmune etiology is suggested to
be involved in the pathogenesis of Tourette’s syndrome (TS),
we investigated oligoclonal bands (OB) of immunoglobulin G
(IgG) in cerebrospinal fluid (CSF), indicating a humoral immune
response in the central nervous system. CSF examinations
including isoelectric focusing to analyze the presence of OB
were performed in 21 TS patients [17 men/4 women, mean
age 5 29 6 12 (SD) years]. Isoelectric focusing showed the
presence of positive OB in 6, borderline bands in 2, and se-
rum and CSF bands (‘‘mirrored pattern’’) in another 2 patients.
Clinical data did not correlate with CSF findings. Thus, 38% (8
of 21) of our patients exhibited pathological CSF bands. Since
none of them suffered from another disease known to be
associated with OB, our results suggest an association with
the pathogenesis of TS itself and point to an involvement of
immunological mechanisms in TS pathology. VC 2010 Move-
ment Disorder Society
Key Words: tics and Tourette’s syndrome; neuro-
immunology
Tourette’s syndrome (TS) is a chronic disorder char-
acterized by multiple, waxing and waning, motor and
vocal tics. Genetic as well as environmental factors
have been associated with the pathogenesis of TS.1–3
Because Sydenham’s chorea (SC), an immune-medi-
ated disease caused by group A b-hemolytic strepto-
cocci (GABHS), and TS both are characterized by
hyperkinetic movements and behavioral alteration and
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affect comparable anatomical areas, a common etiol-
ogy has been suggested in these disorders.4 Accord-
ingly, the term Pediatric autoimmune neuropsychiatric
disorder associated with streptococcal infections
(PANDAS) has been suggested for patients suffering
from tics or obsessive-compulsive disorder (OCD) in
which a GABHS infection preceded symptoms’ onset.
In PANDAS it is proposed that GABHS antibodies
cross-react with basal ganglia antigens and trigger an
immunological process.4 Although several data sup-
port an immunological dysregulation in TS, the etiolo-
gic significance of GABHS infection as well as the
exact mechanisms remain in doubt.5–7 Extensive
research on antistreptococcal and antineuronal anti-
bodies has led to different results.8–10
So far, extensive research has focused on serological
examinations in TS, but little is known about immuno-
logical findings in cerebrospinal fluid (CSF). Detection
of oligoclonal bands (OB) of immunoglobulin G (IgG)
in CSF by isoelectric focusing provides a sensitive
method for qualitative detection of humoral immune
response. Whereas OB in CSF (but not in serum) indi-
cate a local antibody synthesis (e.g., in multiple sclerosis
or encephalitis), identical (‘‘mirrored’’) bands in CSF
and serum point to a systemic immune response (e.g., in
Guillain-Barré-Syndrome or rheumatologic diseases).11
Here, we report the results of CSF analyses in 21 TS
patients as CSF findings seem particularly interesting and
might contribute further details of immune dysregulation.
Methods
Patients
Between 1993 and 2004 a lumbar puncture (LP) was
performed in 21 patients [17 men, 4 women, mean age
¼ 29 6 12 (SD) years, range, 9–51] with TS according
to DSM-III R criteria attending our Tourette outpatient
clinic for a thorough diagnostic assessment. Tic severity
according to the Shapiro Tourette Syndrome Severity
Scale (STSS)12 was 3.6 6 1.4 (range, 1–5). The mean
age of tic onset was 7.0 6 3.1 years (range, 3–17). Fur-
ther clinical details are summarized in Table 1. Neuro-
logical and general examinations, routine blood and
urine tests, microbiological and virological investiga-
tions in serum and CSF, and cranial MRI were normal
in all patients. None of the patients had a history of SC
or any other disease suggesting the diagnosis of second-
ary tics or suffered from a concomitant disease known
to be associated with OB. At the time of LP none of the
patients suffered from an acute infection. Thirteen of 21
patients underwent follow up after 2 to 14 years (mean,
8.9 6 4.0). All patients delivered written informed con-
sent before entering the study. Ethics approval had been
obtained.
CSF Examinations
CSF examinations were performed at the CSF labo-
ratory, Hannover Medical School, and included cell
count and cytology differentials. Total protein was
determined with a Coomassie-Blue dye binding
method, while albumin and IgG were estimated by
nephelometry in paired serum and CSF samples. The
state of the blood-CSF-barrier was evaluated by the al-
bumin quotient (albumin[CSF]/albumin[serum]) with
age-corrected cut-offs [(age/15)þ4)] as well as the
hyperbolic formula of Reiber. Quantitative intrathecal
IgG production was calculated by the IgG index
[(IgG[CSF]  albumin[serum])/(IgG[serum]  albu-
min[CSF])]. Isoelectric focusing (IEF) was performed
on macro polyacrylamide gels with automated silver
staining to analyze the presence of OB as described
previously.11,13 All IEF analyses were performed by
the same person (UW). Positive OB was defined as 4
bands, borderline bands as 2–3, and negative bands as
1 band. IEF was done simultaneously in CSF and se-
rum samples to differentiate identical (‘‘mirrored’’)
patterns of bands in both serum and CSF from oligo-
clonal IgG responses in CSF.
Statistical Analysis
The significance of differences in tic severity (STSS),
age of tic onset, and medication between patients with
and without OB was assessed using independent sam-
ples t test. A value of P < 0.05 was regarded as statis-
tically significant.
TABLE 1. Clinical details of TS patients
No. Age at LP/sex Medication Age of onset STSS follow-up (years)
1 46/W BZD unknown 4 7
2 9/M – 6 2 8
3 33/M NL, CBZ 6 5
4 41/M – 4 3 7
5 29/M NL, SRI 17 2 2
6 20/M SRI 4 5 8
7 51/M – 11 3 4
8 17/M NL, BZD 4 1
9 20/M NL 8 2
10 20/M NL, BIP, VLP 8 5 14
11 37/M – 7 5 14
12 24/M – 5 2
13 29/M NL, BZD 3 3 14
14 21/W NL 9 5 5
15 38/M SRI 7 3 4
16a 34/W NL 6 5
16b 36/W NL, SRI 6 5
17 13/M NL, BZD 9 5 8
18 13/M NL, BZD 8 5 9
19 32/W NL 5 5
20 34/M NL, SRI 7 4
21 40/M – 6 2
W ¼ woman, M ¼ man, BZD ¼ benzodiazepine, NL ¼ neuroleptics, CBZ ¼
carbamazepine, SRI ¼ serotonin re-uptake inhibitor, VLA ¼ valproate, BIP
¼ biperidene, STSS ¼ Shapiro Tourette syndrome severity scale, No.16a/
No.16b ¼ in this woman lumbar puncture was performed twice at a 2-year
interval, No.17/No.18 ¼ monozygotic twins.
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Results
Three patients demonstrated a marginal pleocytosis,
whereas cytology differentials were normal in all
patients (Table 2). Total protein was slightly elevated
in 5 patients. With age-corrected cut-offs 3 patients
displayed minor alterations of the albumin quotient
indicating a minimal disturbance of the blood-CSF-
barrier. The IgG index as well as the hyperbolic for-
mula of Reiber as a measure of quantitative intrathe-
cal IgG synthesis was normal in all patients. In
contrast, the more sensitive qualitative method of oli-
goclonal IgG detection by IEF showed positive OB in
6 patients, borderline bands in 2, and a mirrored pat-
tern in serum and CSF in 2 patients (Table 2).
When correlating clinical data to CSF findings no
association with age, age at tic onset, sex, medication,
and tic severity (STSS) could be demonstrated.
In 1 patient (no. 16) LP was done twice, at the age
of 34, respectively 36 years. Whereas the first exami-
nation exhibited borderline bands plus identical bands
in serum and CSF, the second analysis demonstrated
positive OB plus identical bands.
CSF analyses in a pair of identical twins (13-year-
old boys) showed positive OB in one (no. 18) but no
intrathecal OB synthesis in the other twin (no. 17),
(Table 2). The twin exhibiting positive OB had an ear-
lier age of onset.
In 7 patients antistreptolysin O (ASO)-titers had
been investigated in serum samples at time of LP and
were significantly increased in 3 patients. Two of them
(no. 10, 19) showed normal CSF findings; only one
exhibited positive OB (no. 14). Patients exhibiting
normal ASO-titers showed either borderline bands
(no. 4), a mirrored pattern (no. 15), or a normal CSF
analysis (no. 13, 20), (Table 2).
Discussion
This is the first study investigating OB in CSF in
patients suffering from TS. Whereas cell count, cytol-
ogy examination, albumin quotient, and IgG index
showed no significant alterations, we found positive
(4) or borderline (2–3) bands in 8 of 21 (38%)
patients and a mirrored pattern in another 2 patients.
Neither additional investigations nor the past medical
history or follow-up investigations (over a period of
2–14 years) suggested the coexistence of other diseases
known to be associated with OB in one of these
patients. Since OB provide evidence for the occurrence
of a humoral immune response, our results strongly
point to an autoimmune process in at least a subgroup
of TS patients. Moreover, our data suggest that an in-
trathecal as well as a systemic immune response may
occur in TS, even in a single patient. It can be ruled
out that CSF bands are without any significance
TABLE 2. CSF analyses (cell count, cytology, total protein, albumin quotient, IgG index, OB) and antistreptolysin O

















1 1.3 normal 0.297 3.6 0.535 0 –
2 2.7 normal 0.309 3.3 0.471 þCSF –
3 1.7 normal 0.393 4.1 0.516 (þ)CSF –
4 4.7 normal 0.402 4.6 0.420 (þ)CSF 84
5 1.3 normal 0.514 5.1 0.449 0 –
6 1.0 normal 0.307 2.7 0.472 0 –
7 1.0 normal 0.396 4.4 0.495 0 –
8 1.7 normal 0.521 5.7 0.521 0 –
9 3.7 normal 0.506 6.2 0.542 0 –
10 2.3 normal 0.291 2.9 0.492 0 990
11 6.3 normal 0.512 7.6 0.482 identical –
12 5.0 normal 0.342 3.4 0.502 þCSF –
13 2.7 normal 0.485 5.9 0.484 0 106
14 3.3 normal 0.304 3.9 0.434 þCSF 214
15 1.7 normal 0.443 5.6 0.455 identical 94
16a 2.7 normal 0.323 3.2 0.546 (þ)CSF plus identical –
16b 2.0 normal 0.352 3.2 0.490 þCSF plus identical –
17 1.7 normal 0.292 2.4 0.480 0 –
18 2.0 normal 0.276 2.3 0.546 þCSF –
19 0.7 normal 0.325 4.3 0.431 0 410
20 0.7 normal 0.430 6.0 0.513 0 61
21 2.3 normal 0.550 6.0 0.609 þCSF –
Alb ¼ albumin, þCSF ¼ CSF-restricted OB, (þ)CSF ¼ borderline bands in CSF, identical ¼ identical (mirrored) bands in serum and CSF, IgG¼ immunoglobulin
G, OB ¼ oligoclonal bands, IEF ¼ isoelectric focusing, ASO ¼ antistreptolysin O.
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because in healthy control subjects they occur only in
a minor degree of 3%.14
Follow-up investigation in 1 patient showed repro-
ducible intrathecal IgG synthesis and, therefore, pro-
vides evidence that OB might be a permanent rather
than a temporary phenomenon in TS.
Remarkably, CSF analyses in a pair of identical
twins yielded different results with positive OB in one,
but no CSF abnormalities in the other twin. These
findings suggest that OB are due to environmental and
not to genetic factors. It is remarkable that the twin
exhibiting OB had an earlier onset of tics (8 years)
compared to his brother (9 years) suggesting that
immunologic factors might contribute to TS as an epi-
genetic factor mediating tic onset.
Comparable to our data, Church et al.,15 demon-
strated oligoclonal IgG responses in 2 of 13 patients
(¼ 15%) with acute SC. This relatively small number
of positive responses—despite proven underlying
immune mechanism—has been explained by the small
sample size and the fact that inflammation in SC is re-
stricted to a focal brain region.15
Although ASO-titers had been analyzed in only 7 of
our patients at the time of lumbar puncture, our data
do not suggest an association between OB and ASO-
titers. This observation is in line with a report by Kies-
sling et al.16 They described a patient suffering from
tics and comorbid attention deficit hyperactivity disor-
der (ADHD) who exhibited positive streptococcal
titers and elevated antineuronal antibodies in CSF and
serum, but no intrathecal OB synthesis.
Some limitations of our study have to be addressed:
first, the sample size is relatively small. However, to the
best of our knowledge, this is the first report of OB in
TS. Second, follow-up LP was performed in only 1
patient. Third, frequency of OB depends heavily on the
chosen limit of bands: according to an international con-
sensus, two bands in CSF are sufficient to assume local
IgG synthesis; in our laboratory two to three bands are
rated as borderline, and four or more as positive. Thus,
high sensitivity and specificity are retained; however, a
smaller number of positive results are obtained. Fourth,
ASO-titers were measured in only one third of our
patients and merely once at time of lumbar puncture.
Therefore an association cannot entirely be excluded.
In conclusion, our results demonstrate that oligoclo-
nal CSF bands are a common feature in TS. Our data
provide evidence that the intrathecal synthesis of OB
might be a permanent phenomenon caused by envi-
ronmental rather than genetic factors. It remains
unclear whether autoimmune mechanisms may con-
tribute to TS pathology (at least in a subgroup of
patients) or represent an epiphenomenon to another—
so far unknown—etiologic factor.
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ABSTRACT
Rapid eye movement (REM) sleep disorders are commonly
associated to patients with spinocerebellar ataxia type 2
(SCA2); however, these abnormalities have not been studied
in presymptomatic gene carriers. To determine whether the
REM sleep pathology is detectable before clinical manifesta-
tion of SCA2 and evaluate it as a preclinical biomarker, we
studied 36 presymptomatic SCA2 individuals and 36 controls
by video-polysomnography (VPSG) and sleep questionnaires.
Presymptomatic subjects showed significant decrease of REM
sleep percentage, REMs density, total sleep time, and sleep
efficiency. Aging effect on REM sleep percentage was signifi-
cant in both groups. There was no correlation between cyto-
sine-adenine-guanine (CAG) repeat length and REM sleep.
Our findings identified the REM sleep pathology as a promi-
nent herald sign of SCA2, conferring a special importance to
VPSG as a sensitive neurophysiological tool to detect early
changes associated with SCA2, which contributes to the
understanding of disease pathophysiology and the develop-
ment of therapeutic trials focused on the preclinical disease
stage. VC 2010 Movement Disorder Society
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Spinocerebellar ataxia type 2 (SCA2) is an autoso-
mal dominant cerebellar ataxia caused by the expan-
sion of CAG repeats in the ATXN2 gene, and
therefore, the expression of an expanded polyglut-
amine tract in the ataxin 2 protein is responsible for
the neurodegeneration of cerebellum, brainstem, sub-
stantia nigra, thalamus, and other structures.1 The dis-
ease is characterized by a progressive cerebellar
syndrome,2 saccadic slowing,3,4 sensory peripheral
neuropathy,5,6 cognitive dysfunction,7 and sleep disor-
ders.8,9 Worldwide, the highest prevalence of SCA2 is
in the Holguin province (Cuba), where there are more
than 400 patients and 2,000 first-degree relatives,
resulting from a founder effect.10
Although sleep disorders have been documented in
patients with SCA2,8,9 there are no clues whether
these abnormalities appear before the ataxia onset. In
view of the early pons atrophy1 in SCA2 and the rele-
vance of this brain area for rapid eye movement
(REM) sleep,11 we assessed sleep performance in 36
presymptomatic SCA2 individuals and 36 age- and
sex-matched control individuals with the aim to iden-




Thirty-six presymptomatic SCA2 gene carriers (11
males and 25 females) with ages ranging from 20 to
59 years [mean: 34.9; standard deviation (SD): 9.9],
CAG repeat lengths from 32 to 43 units (mean: 36.5;
SD: 2.9), and scores of Scale for the Assessment and
Rating of Ataxia (SARA)12 ranging from 0 to 3
(mean: 0.54; SD: 0.92) were admitted to the Center
for the Research and Rehabilitation of Hereditary
Ataxias in Holguin for this study. Thirty-six healthy
individuals (aged from 18 to 63 years, mean: 36.0;
SD: 10.7; and SARA scores from 0 to 1, mean: 0.11;
SD: 0.36) were randomly chosen as age-and sex-
matched controls. No subject was under any medica-
tion that would have interfered with sleep or polysom-
nographic findings. The study was approved by the
Institutional Ethics Committee and was conducted
according to the Declaration of Helsinki. Each subject
gave written informed consent for the participation in
the study.
Sleep Quality Measures
All subjects completed the Pittsburgh Sleep Ques-
tionnaire Inventory (PSQI)13 to assess sleep quality
and the Epworth Sleepiness Scale (ESS)14 to document
daytime sleepiness. Also, the subjects and/or their bed
partners were interviewed to diagnose the REM
behavior disorder (RBD), restless legs syndrome
(RLS), and nocturnal cramps.
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Video-Polysomnographic Recordings
All subjects underwent video-polysomnographic
(VPSG) recordings for two consecutive nights during
their routine sleeping hours. Polysomnography was
performed with a digital polygraph (MEDICID V.
Neuronic S.A, Havana, Cuba) using an standard mon-
tage, which included electroencephalographical (EEG)
recording by F3, F4, C3, C4, O1, O2, A1, and A2
electrodes, vertical and horizontal electroculography
(EOG), electrocardiography, and electromyography
(EMG) of mental and both tibialis anterior muscles.
Respiration monitoring included nasal airflow, tra-
cheal microphone, thoracic and abdominal respiratory
effort, and oxygen saturation. To exclude first night
effects, results of the second night were only analyzed.
Sleep was scored according to the criteria of
Rechtschaffen and Kales.15 As presymptomatic SCA2
subjects showed slowing of saccadic movements,4
which could affect the REM sleep scoring, we paid
special attention to the EMG and EEG features of
REM sleep, particularly to the apparition of sawtooth
waves as evidence of REM sleep because these EEG
waves are closely related with the bursts of REMs.
Also, the REMs were visually counted from minimum
peak-to-trough amplitudes of 25 lV. REMs density
was calculated as the percentage of 3-second minie-
pochs of REM sleep with at least one REM.8 The
tonic and phasic components of REM sleep were
scored separately as suggested by Lapierre and Mont-
plaisir.16 The evaluation of respiratory variables17 and
periodic leg movements (PLMs)18 were performed
using standard criteria.
Statistical Analysis
Statistical analyses were done using the Kolmo-
gorov-Smirnov test to assess the normality of all varia-
bles, t test to compare the means of clinical and VPSG
variables between subjects and controls, v2 test to
compare the frequency of REM sleep abnormalities
between groups, and correlation analyses to determine
factors influencing sleep disorders.
Results
Nineteen (52.8%) of 36 presymptomatic SCA2 indi-
viduals and 29 (80.6%) of 36 controls reported good
subjective sleep quality estimated by PSQI scale;
nevertheless, the remaining 7 controls reached the
minimum abnormal score (5 points). PSQI total score
ranged from 0 to 14 points in the presymptomatic
subjects (mean: 4.94; SD: 3.11) and 0 to 5 in the con-
trols (means: 3.06; SD: 1.45), with significant inter-
group differences (P ¼ 0.002).
None of the subject had a history of RBD or RLS.
One (2.79%) and 10 (27.88%) of 36 presymptomatic
SCA2 individuals reported a history of bruxism and
nocturnal cramps, respectively. There were no signifi-
cant differences between both groups for the ESS
scores (presymptomatic subjects: mean: 6.58, SD:
3.06; controls: mean: 5.36, SD: 2.49; P ¼ 0.592).
The VPSG variables measured in both groups are
shown in Table 1. The SCA2 mutation carriers
showed significant decrease of REM sleep percentage
and REMs density, as well as reduction of sleep period
time (SPT), total sleep time (TST), and sleep efficiency
when compared with controls. The remaining VPSG
variables were normal in presymptomatic subjects.
Nineteen (52.8%) of 36 presymptomatic SCA2 indi-
viduals had REM sleep percentages below normal lim-
its (15% of SPT), whereas only 3 controls (8.33%)
showed abnormal values of REM sleep amounts (v2 ¼
16.76; P < 0.0001). The EEG and EMG features of
REM sleep in presymptomatic SCA2 subjects were
normal, which allowed us to adequately score the
TABLE 1. Video-polysomnographical (VPSG) variables in SCA2 presymptomatics (n ¼ 36) compared with matched
controls (n ¼ 36)
PSG sleep variables SCA2 presymptomatics Healthy controls P value
Total record time (TRT) (hr) 7.61 6 0.69 7.89 6 0.44 0.096
Sleep period time (SPT) (hr) 7.13 6 0.61 7.61 6 0.44 <0.001
Total sleep time (TST) (hr) 6.00 6 1.02 7.09 6 0.68 <0.001
Sleep efficiency (%) 81.71 6 9.14 91.19 6 3.33 <0.001
Arousal index 13.32 6 10.18 11.69 6 9.89 0.119
Sleep onset latency (min) 14.83 6 11.81 13.5 6 8.5 0.603
REM sleep onset latency (min) 88.73 6 31.58 82.83 6 34.43 0.476
Wake (%) 12.85 6 5.91 8.58 6 7.91 0.127
Stage 1 non-REM (%) 8.26 6 3.99 7.35 6 4.58 0.371
Stage 2 non-REM (%) 46.12 6 10.09 47.80 6 8.17 0.444
Stage 3 non-REM (%) 5.20 6 1.90 5.21 6 1.76 0.981
Stage 4 non-REM (%) 10.31 6 6.32 12.32 6 6.34 0.186
REM sleep (%) 13.50 6 4.86 19.82 6 4.11 <0.001
REMs density (%) 13.57 6 6.69 29.66 6 11.92 <0.001
Values are means 6 SD. Student’s t test (two tailed). The bold values indicates mean significant differences between both groups.
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REM sleep epochs in spite of the reduced EOG
activity.
In both groups, age showed a significant correlation
with REM sleep percentage (presymptomatic subjects:
r ¼ 0.36; P ¼ 0.035; controls: r ¼ 0.37; P ¼
0.033; Fig. 1) and TST (presymptomatic subjects: r ¼
0.52; P ¼ 0.002; controls: r ¼ 0.35; P ¼ 0.048),
as well as with sleep efficiency (r ¼ 0.61; P < 0.001)
and percentage of wake periods (r ¼ 0.61; P < 0.001)
in presymptomatic subjects. No sleep variable corre-
lated either with PSQI, ESS, or SARA scores in both
groups or with CAG repeats in presymptomatic
subjects.
PLMs were observed in 1 (2.78%) of 36 presympto-
matic SCA2 individuals without intergroup differen-
ces. Also, no differences were found on sleep
respiratory variables.
Discussion
This is the first study that investigated the sleep dis-
orders in a large cohort of presymptomatic SCA2
mutation carriers and their sex- and age-matched con-
trols by sleep questionnaires and VPSG. Neurological
examinations could not differentiate among presymp-
tomatic SCA2 individuals and controls, confirming the
preclinical status of the presymptomatic cohort and
coinciding with a previous study that found normal
subjects showing SARA scores as high as 7.12
Subjective sleep quality measured by PSQI and ESS
scales revealed no considerable sleep symptomatology
in presymptomatic SCA2 carriers, which conferred a
special importance to VPSG analysis. Indeed, we have
demonstrated that presymptomatic SCA2 mutation
carriers show early REM sleep disorders manifested
by the decrease of REM sleep percentage and REMs
density, which had been previously observed in
patients with SCA2.8,9 The reduction of REM sleep in
the presymptomatic subjects contributed to the
decrease of TST and sleep efficiency.
Correlation analyses disclosed a significant effect of
age on REM sleep percentage in presymptomatic
SCA2 individuals and controls, coinciding with previ-
ous reports.19,20 In both groups, the correlation coeffi-
cients between age and REM sleep were very similar,
which suggest that the age-dependent decrease of
REM sleep in the presymptomatic cohort is not an im-
portant cause of this preclinical sleep disorder.
We considered that the decrease of REM sleep in
presymptomatic SCA2 subjects was not caused by
detection failures resulting from the reduced eye veloc-
ity,4 because the REMs were scored from a minimum
amplitude of 25 lV and the EEG and EMG features
of REM sleep were easily detectable. Also, considering
that saccade velocity is strongly influenced by the
CAG repeat size,4 it was expected that subjects with
larger CAG repeats showed the lowest REM sleep
amounts; however, no significant correlation between
these variables was observed.
The REM sleep abnormalities showed by presymp-
tomatic SCA2 individuals suggest an early dysfunction
or neurodegeneration of REM-ON neurons in the
pons. Nevertheless, consistent neuropathological and
imaging studies in presymptomatic SCA2 subjects are
mandatory to confirm the preclinical pontine involve-
ment in SCA2, because pontine dysfunction in preclin-
ical SCA2 has been demonstrated only in one subject
by positron emission tomography.21
The reductions of REM sleep percentage and REMs
density before the ataxia onset have not been reported
in other SCA subtypes. Nonetheless, we cannot assure
that these sleep abnormalities are SCA2 specific,
because the lack of VPSG studies could underestimate
these REM sleep disorders in asymptomatic carriers of
these mutations. In fact, other REM sleep disorder,
such as RBD, was previously observed in three asymp-
tomatic SCA3 mutation carriers.22,23
In conclusion, this work indicates that the decrease
of REM sleep percentage and REMs density are prom-
inent sleep disorders that herald the onset of SCA2 in
presymptomatic mutation carriers. Therefore, VPSG is
a sensitive neurophysiological tool to detect early
changes associated with SCA2, and consequently, it
may be useful to understand the disease pathophysiol-
ogy from asymptomatic stages, which acquires a fun-
damental relevance for the development of future
therapeutic options designed to delay the clinical dis-
ease onset.
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Poewe W. Disturbance of rapid eye movement sleep in spinocere-
bellar ataxia type 2. Mov Disord 2006;21:1751–1754.
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